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ABSTRACT 
The objective of the present study is to address some important questions related 
to prostate cancer treatments and survivorship among White and African American men. 
It is commonly understood that the risk of developing prostate cancer is higher in African 
American men than the other races. However, using parametric analysis, this study 
demonstrates that this perception is a “myth” not a “reality”.  The study further identifies 
the existence of racial/ethnic disparities by comparing the average mean tumor size, the 
median of survival time, and the survival function between White and African American 
men. These results underline the necessity of understanding the role of racial background 
in working towards improved clinical targeting, and thereby, improving clinical 
outcomes. Furthermore, parametric survival analysis was performed to estimate the 
survivorship of white men undergoing different treatments at each stage of prostate 
cancer. Additionally, to better understand the risk factors (age, tumor size, the interaction 
between age and tumor size) associated with survival time, an accelerated failure time 
model was developed that could accurately predict the rates of survivorship of white men 
at each stage of prostate cancer in accordance with whatever treatment they had received. 
Finally, the results of parametric survival analysis and the accelerated failure time model 
are compared among white men undergoing similar treatment at each stage of the disease. 
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CHAPTER 1 REVIEW OF PRESENT STUDIES 
This chapter starts with an important health issue, namely cancer. In particular, a 
review of prostate cancer along with an overall schematic diagram is presented.  In 
addition, we discuss an overview of survival analysis along with accelerated failure time 
model that are relevant to the present study.  Finally, we introduce the significant 
research problems in the manuscript.
1.1 Cancer 
Cancer is a term used for diseases characterized by out-of-control cell growth. There 
exist over 100 different types of cancer and are named for the organ or type of cell that is 
initially affected. The estimated of new cancer cases in 2013 are 1,660,290 and 
approximated 580,350 cancer deaths occur in the United States. All cancers involve 
uncontrollable cell growth and divided, but about 5% of all cancers are caused by internal 
factors (inherited mutations, hormones, immune conditions, and mutations that occur 
from metabolism). About 90-95% of cancer is caused by external factors (tobacco, 
infectious organisms, chemicals, and radiation). 
1.2 Prostate Cancer 
Prostate cancer is the second most common cancer in men that starts in the 
prostate gland (American Cancer Society). The prostate is a walnut-sized gland located in 
the male reproductive system. The function of the prostate is to produce fluid that 
protects and nourishes sperm cells in semen. The seminal vesicles behind the prostate 
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gland produce most of the fluid for semen. The prostate wraps around the urethra, the 
tube that carries urine and semen out of the body (American Cancer Society and National 
Institute of Health). Most prostate cancers are slow growing; however, there are a 
significant number of cases of aggressive prostate cancers that can be very devastating. 
The cancer cells may metastasize (spread) from the prostate to other parts of the body, 
particularly the bones and lymph nodes.  Prostate cancer may cause pain, difficultly in 
urinating, problems during sexual intercourse, or erectile dysfunction. Other symptoms 
can potentially develop during later stages of the disease. The early stage of prostate 
cancer usually has no symptoms. However, based on the patient’s level of risk, most 
physicians recommend going through the screening test. The most common method of 
screening is Prostate-Specific Antigen (PSA) test, a protein produced by cells of the 
prostate gland. The PSA test measures the level of PSA in a man’s blood. PSA levels of 
4.0 ng/mL or lower is considered as normal. Thus, patients would often undergo prostate 
biopsy if they had PSA level above 4.0 ng/mL. However, prior research revealed that 
there existed issues in interpreting the PSA test results. The PSA level may be high due to 
an enlarged prostate, but not cancer or it may be low but cancer is present (A. Qaseem, 
2013). Furthermore, the PSA test might be no benefit for the patients and be substantial 
harms from the treatment of prostate cancer (A. Qaseem, 2013). The other prostate cancer 
screenings are urine test and digital test.  
Researchers had reported several risk factors related to prostate cancer (J.M.Chan, 
1998; S.M. Lesko, 1996). Some of the risk factors include: age (> 60 years), the size of 
tumor, family history of prostate cancer, abuse of alcohol, and an overweight of body 
mass index (BMI). The distribution of developing prostate cancer was 30% for men in 
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their 30s, 50% in their 50s, and more than 75% for those older than 85 in the United 
States (Sakr, 1993).  In 2012, the median age of men at diagnosis was 64.5 years 
(Wolfgang Lilleby, 2012). A report showed that the risk of dying of prostate cancer was 
independently associated with younger age at diagnosis (Lilja et al., 2011). Thus, men 
should consult their medical doctor regularly in order to improve the prostate cancer 
survival rate (Brawley, 2012). The size of tumor is also a high risk factor for prostate 
cancer. A research showed that as the size of tumor increased, the chance of the tumor 
being malignant increased exponentially (Y.M. Chan, 2012). In fact, tumor cell was 
related to the risk of prostate cancer death in patients under watchful waiting (Andreas 
Josefsson, 2012). Therefore, patients should take prostate cancer treatments into account 
when diagnosed with prostate cancer. The other high risk factors researchers had 
identified were family history, smoking, alcohol, fruit and vegetable (Adam S. Kibel, 
2012; Floyd J. Fowler, 2012; Jordan A. Holmes, 2012; Ping Tang, 2012; Rossi, 2012; W. 
H. Hall, 2005).  
The decision making of prostate cancer treatments are particularly important for 
the patients diagnosed with prostate cancer. There are a number of prostate cancer 
treatments such as radiation therapy, surgery, and combination of radiation and surgery in 
today’s knowledge society. A considerable amount of research has shown that some 
treatments might have better performance than others. A study conducted to explore 
racial differences in treatment discussed, preferred and ultimately received for localized 
prostate cancer, has revealed that health professionals were more likely to discuss surgery 
and watchful waiting with Whites than Hispanics. African Americans on the other hand, 
were less likely to receive watchful waiting. However, they preferred and received 
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radiation therapy. In general, patients who preferred surgery and radiation therapy 
showed a higher agreement for what was actually received (G. M. Monawar Hosain, 
2012). Furthermore, a surgical delay of 6 months or more had lower survival rate. Those 
patients with a surgical delay of 6 months or more were found in older age and African-
American men (O'Brien et al., 2011). Because the treatment options have different side 
effect, the decisions of prostate cancer treatment are particularly important for the 
patients (Snyder et al., 2010). 
1.3 Research Data 
The SEER Program 
The Surveillance, Epidemiology, and End Results (SEER) program was funded 
by the National Cancer Institute in 1973. The SEER program is a coordinated system to 
collect data on patient demographics, primary tumor site, specific cancer markers, cancer 
stage at diagnosis, first course of treatment, and patient survival across the United States. 
The SEER program currently collects population-based cancer registries from 20 U.S. 
geographic areas, including Alaska Native Tumor Registry, Arizona Indians, Cherokee 
Nation, Connecticut, Detroit, Greater California, Hawaii, Iowa, Kentucky, Los Angeles, 
Louisiana, New Jersey, New Mexico, Seattle-Puget Sound, Utah, and the metropolitan 
areas of Atlanta, Greater Georgia, Rural Georgia, San Francisco-Oakland and San Jose-
Monterey. Approximately 28% of the total U.S. population were covered by these areas 
and represented the demographics of the entire U.S. population such as race/ethnicity, 
urban as well as rural residents.   
5 
 
Who Uses SEER Data, and what do They Use the Data for? 
SEER data has become increasingly popular in health research. Thousands of 
researchers, clinicians, cancer registrars, public health officials, legislators, policymakers, 
community groups, and members of the public have widely used the data on varies of 
applications and obtained significant results. For instance, they evaluated cancer 
prevention and screening programs and the quality of cancer care, identified racial and 
gender disparities, demonstrated the effectiveness of public health interventions, and 
translated the research into health policy and practice. Due to the fact that many 
professions make use of the SEER data, it is essential to maintain and improve the quality 
of the data. 
How do SEER Registries Maintain Data Quality? 
SEER’s Quality Improvement (QI) team plays an important role in maintaining 
data quality. Each SEER registries and external contractors are assigned SEER QI team 
from National Cancer Institute. The responsibilities of this team include: standardize 
medical coding and summary writing by cancer registrars, individuals who collect and 
code cancer patient data, educate and train cancer registrars, evaluate the consistency and 
accuracy of coding by cancer registrars, and prepare databases and the guideline that 
describe coding rules. 
How is SEER Data Disseminated? 
SEER data has been classified into five categories in order to provide an effective 
way for researchers seeking information and performing data analysis. The details of the 
five categories are described as following:  
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Online Cancer Statistics 
 Cancer Stat Fact Sheets involved descriptive statistics for common cancer types. 
 Fast Stats is a tool to create tables and graphs of cancer statistics for major cancer 
sites by age, sex, race, and time period. 
 Cancer Query Systems is similar to Fast Stats but it can provide more flexibility 
and a larger set of cancer statistics. 
 State Cancer Profiles provides maps and graphs for prioritizing cancer control 
activities. 
Data Analysis Tools 
 SEER*Stat is a software used to analyze SEER data. 
 Joinpoint is a software used to analyze trends in data. 
 DevCan is a software used to calculate lifetime risks of getting or dying from 
cancer. 
 HD*Calc is a software that generates summary measures for evaluating and 
monitoring health disparities. 
Reports 
 SEER Cancer Statistics Review (CSR) is an online searching report using tables 
showing cancer statistics by race, sex, age, and year of diagnosis. 
 Annual Report to the Nation on the Status of Cancer is an annual update report on 
U.S. cancer occurrence and trends. 
 United States Cancer Statistics is state-specific cancer incidence and mortality 
data. 
7 
 
Studies 
 Rapid Response Surveillance Studies (RRSS) is to address issues in cancer 
control and prevention by collecting biological materials and/or information via 
surveys, interviews, and medical record reviews. 
 Patterns of care studies (part of RRSS) are to evaluate the use of state-of-the-art 
cancer therapy in community practice. 
Databases and Linkages to Other Data 
 SEER-Medicare Database can link to SEER data and Medicare enrollment and 
claims files. 
 SEER-Medicare Health Outcomes Survey (MHOS) Database provides detailed 
information on elderly cancer patients. 
 National Longitudinal Mortality Study (NLMS) & Linked SEER-NLMS 
Databases investigate relationships between socioeconomic status and cancer 
burden. 
Overall Prostate Cancer Data 
The SEER program reported that it is estimated 238,590 men will be diagnosed 
with prostate cancer and 29,720 men will die for cancer of the prostate in the year of 
2013. From 2005-2009, the median age at death for cancer of the prostate was 80 years of 
age. Approximately 0.0% died under age 20 and between 20 and 34; 0.1% between 35 
and 44%, 1.5% between 45 and 54; 8.0% between 55 and 64; 19.8% between 65 and 74; 
38.6% between 75 and 84; and 32% 85+ years of age. The overall 5-year relative survival 
for 2002-2008 was 99.2%. Five-year relative survival by race was: 99.6% for white men; 
96.2 for black men. An overall schematic network diagram is given by Figure 1.1. 
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Figure 1.1 Overall Schematic Network Diagram of Prostate Cancer 
1.4 Parametric Analysis 
Parametric analysis is a branch of statistics that assumes the data has come from a 
type of probability distribution. Based on the specific probability distribution, we can 
obtain the inference statistics about the parameters.  It is commonly understood that 
African American men are more likely to have prostate cancer than Whites. In chapter 2, 
the objective is to investigate if this is a myth or reality and performs basic parametric 
analysis that can be used effectively to learn more about the subject cancer. We first 
identify the probability density function (PDF) that characterizes the malignant tumor 
size by race. In addition, the useful information such as expected malignant tumor size 
along with its variance and confidence limits are constructed based on the probability 
distribution. There is an exponential growth behavior between the size of a tumor and the 
chance of the tumor being malignant. Thus, a prostate cancer patient with a tumor size of 
one millimeter would expect to have 99.52% chance for the tumor to be malignant. 
Prostate 
Cancer 
Patients 
(479,204) 
Patients with 
Survival Time 
(23,714) 
Whites 
Stage I 
Stage II 
Stage III 
Stage IV 
African 
Americans 
Stage I 
Stage II 
Stage III 
Stage IV 
Patients with 
Tumor Size 
(23,610) 
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Malignant 
Benign 
African 
Americans 
Malignant 
Benign 
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Furthermore, results showed that the average tumor size for Whites is statistically larger 
than African Americans. With these findings, we would expect the risk of developing 
prostate cancer to be higher in Whites than African Americans. However, hypothesis test 
comparing the proportion of Whites with malignant tumor given tumor size and the 
proportion of African Americans with malignant tumor given tumor size revealed that 
there is no statistical difference between the proportion of Whites and African Americans 
with malignant tumor given tumor size. Thus, the concept of African Americans more 
likely to develop prostate cancer than Whites is a myth and not a reality. 
1.5 Survival Analysis 
Survival analysis is a popular method dealing with biological organism and 
failure of mechanical systems. It is also called reliability theory or reliability analysis in 
the field of engineering. In general, survival analysis is a statistical modeling that 
involves time to event data.  An important aspect of survival analysis data is censoring 
and non-normality. Non-normality of the data violates the normality assumption of most 
commonly used statistical method such as multiple linear regressions. Censoring plays an 
important role in defining incomplete information in survival analysis. Two possible 
censoring schemes are right censoring, where it is known that the individuals is still alive 
at a given time, left censoring is known that the individuals has experienced the event of 
interest prior to the start of the study. The other concept in survival analysis is the hazard 
rate. The hazard rate is the probability that an individual will experience an event at time 
t while that individual is at risk for having an event. The objective of using survival 
analysis is to answer the question that what is the probability of a given population which 
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will survive past a certain time? This probability can be the death of a cancer patient or 
failure of equipment. 
Let   is a continuous random variable with probability density function (p.d.f.) 
     and cumulative distribution function (c.d.f.)             . 
The survival function is defined as 
                    ∫       
 
 
  
which gives the probability of being alive at duration  . The survival function is non-
increasing function and always between 0 and 1. 
The hazard function or instantaneous rate of occurrence of the event is defined as 
        
    
                
  
 
    
    
  
 
  
         
In chapter 3, he objective is to perform parametric survival analysis to compare the 
survivorship of prostate cancer patients for Whites by treatments (radiation therapy, 
surgery, combination of radiation and surgery, watchful waiting). In our analysis, we will 
first identify an appropriate probability distribution function that characterizes the 
survival time for Whites and African Americans. We further investigate the existence of 
racial/ethnic disparities and the consistence of the stage of prostate cancer. Finally, we 
compare the survivorship for white men under similar treatment at each stage of prostate 
cancer. In addition, survival probability residual analysis is performed to evaluate the 
average difference in survivorship for white men under different treatments at a particular 
stage.  
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1.6 Accelerated Failure Time Model 
An accelerated failure time model (AFT model) is a parametric model that 
considers the linear relationship between the logarithm of survival time and covariates of 
interests.  Furthermore, we assume the survival time follows a given theoretical 
probability distribution. 
Let    denote a continuous non-negative random variable representing the survival 
time of the  th unit and    be the covariates in the model. The analytical structure of the 
failure model is given by: 
         
 
        
where    is an error term, has a suitable probability distribution such as normal, Weibull, 
or gamma. By exponentiating the equation (3), we obtain a model for the survival time: 
           
 
      
where     is the exponentiated error term.  
In chapter 4, the objective is to perform parametric survival modeling to compare 
the survivorship of prostate cancer patients for Whites by treatments (radiation therapy, 
surgery, combination of radiation and surgery, watchful waiting). In our modeling, we 
consider the risk factors (age at diagnosis, tumor size, and interaction between age at 
diagnosis and tumor size). We first identify gamma is an appropriate probability 
distribution function that characterizes the survival time for white men. We further 
estimate the survival time from the parametric survival model. Finally, we compare the 
survivorship for white men by treatment in the four different stages of prostate cancer 
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using probabilistic analysis. In addition, survival probability residual analysis is 
performed to evaluate the average difference in survivorship for white men under 
different treatments at a particular stage. 
In chapter 5, the objective is to compare the results of parametric survival analysis 
and parametric survival modeling between chapter 3 and chapter 4. We would expect that 
the parametric survival modeling had better results compared with parametric survival 
analysis because the model includes the significant risk factors (age at diagnosis, tumor 
size, and interaction between age at diagnosis and tumor size). We perform to evaluate 
the average percent difference in survivorship for white men under similar treatment at 
each stage of prostate cancer based on the results of chapter 3 and chapter 4. 
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CHAPTER 2 PARAMETRIC ANALYSIS OF PROSTATE CANCER 
The objective of the present study is to perform parametric analysis on the 
malignant tumor size of prostate cancer using real data. It is commonly understood that 
African American men are more likely to have prostate cancer than Whites. We have 
shown that this concept is a “myth” and not a “reality”. We consider the size of the 
cancerous tumor size as the response variable in our statistical analysis. We first identify 
the probability distribution functions that characterize the probabilistic behavior of 
malignant tumor size. In addition to obtaining useful information such as expected value 
along with its variance and confidence limits. We further perform a hypothesis test on 
comparison of average mean tumor sizes between whites and African-American men. 
Furthermore, we examine the relationship between malignancy of tumor and tumor size. 
Finally, binomial analysis was performed to test the proportion of Whites with malignant 
tumors given the tumor size and the proportion of African Americans with malignant 
tumors given the tumor size.
2.1 Background and Data 
Prostate cancer is believed to usually occur in older men (American Cancer 
Society). It has been postulated that the risk of developing prostate cancer is higher in 
African Americans than Whites. The rest of this section is to perform parametric analysis 
to show it is a “myth” and not a “reality”. 
14 
 
We are using real prostate cancer data that was collected from 1973 to 2007 from 
the Surveillance Epidemiology and End Results (SEER) program. This database is a 
premier source for various types of cancers in the United States. They collect information 
on incidence, prevalence and survival from a number of specific geographic areas 
representing 28 percent of the US population and compile reports on all of these regions 
plus cancer mortality for the entire country. The total number of prostate cancer patients 
in this database is 479,204, of which 23,610 have actual tumor sizes. Out of the 23,610, 
there are 23,573 malignant tumors and 37 benign tumors. An extended detail of the 
database is shown by the schematic network diagram given below by Figure 2.1. 
 
Figure 2.1 Prostate Cancer Data Diagram 
In the present study, we address the following questions with respect to prostate cancer.  
 What is the probability distribution function that characterizes the behavior of the 
malignant tumor sizes?  
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 Is there a significant difference in the mean cancerous tumor sizes between 
Whites and African Americans?  
 In general, is tumor size related to the probability of the tumor being malignant?  
 Is the probability of developing prostate cancer higher in African Americans than 
Whites?  
2.2 Probability Distribution and Confidence Limits 
Parametric analysis was performed to determine the best fitted probability 
distribution function that characterizes the malignant tumor size by race. About 40 
different classical distributions were fitted to the data. The three commonly used 
goodness-of-fit tests, Kolmogorov-Smirnov (Stephens, 1974), Anderson-Darling (T.W. 
Anderson, 1952), and Chi-Square (H. Chernoff, 1954) were used to determine the best 
probability distribution function that characterizes each race. We have identified that the 
two best fitted probability distribution functions that characterize the malignant tumor 
sizes for Whites and African Americans using the three goodness-of-fit tests mentioned 
above. The two best fitted probability distribution functions that characterize the 
malignant tumor sizes for Whites are Weibull and Exponential.  
Let x be a random variable. The analytical form of Weibull distribution is given by: 
     
 
 
 
 
 
       ( (
 
 
)
 
)   
where           is continuous shape parameter (   ), and   is continuous scale 
parameter (   ). 
The corresponding cumulative distribution function is given by: 
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Let    as the quantile for which  (  )      where       denotes the CDF. Then, 
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With the maximum likelihood estimates and the quantile  , we can construct a 90 or 95 
percent confident interval under the Weibull distribution. 
The analytical form of exponential distribution is given by: 
                 
where   is continuous scale parameter (   ). 
The corresponding cumulative distribution function is given by: 
     ∫       
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Let    as the quantile for which  (  )      where       denotes the CDF. Then, 
 (  )                  
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With the maximum likelihood estimates and the quantile  , we can construct a 90 or 95 
percent confident interval under the exponential distribution. 
The graph of the Weibull probability density and cumulative distribution functions are 
shown by Figure 2.2, along with estimate of the parameters that are inherent in the 
probability distribution. 
 
Figure 2.2 Fitted Weibull Probability Density Function & Cumulative Distribution Function for Whites 
The maximum likelihood estimates (MLE) for the Weibull probability distribution is 
given by the shape parameter,  ̂         and the scale parameter  ̂         . The 
MLE for Exponential distribution is the rate parameter  ̂         . From the identified 
probability distribution function and their estimates, results of the basic statistics along 
with 90% and 95% confidence limits of the true malignant tumor size is given below in 
Table 2.1. 
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Table 2.1 Fitted Distribution with Estimates and Confidence Intervals for Whites 
Probability 
Distribution 
MLE 
Expected 
Value 
Standard 
Deviation 
90% C.I. 95% C.I. 
Weibull 
 ̂         
 ̂          
13.341 15.374 (0.41004, 43.882) (0.18219, 55.736) 
Exponential  ̂          13.399 13.399 (0.6873, 40.141) (0.33924, 49.429) 
 
The two best fitted probability distribution functions that characterize the malignant 
tumor sizes for African Americans are the Gamma and Weibull. The analytical form of 
gamma distribution is given by: 
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where           is continuous shape parameter (   ), and   is continuous scale 
parameter (   ). 
The corresponding cumulative distribution function is given by: 
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where      
 
 
  is the lower incomplete gamma function. 
Let    as the quantile for which  (  )        where       denotes the CDF. Then, 
 (  )  
     
  
  
    
      
The solution for    is not analytically tractable. However, it can be estimated using 
numerical algorithms in most of the statistical packages. 
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The graph of the Gamma probability density and cumulative distribution functions are 
shown by Figure 2.3, along with the MLE of their parameters. 
 
Figure 2.3 Fitted Gamma Probability Density Function & Cumulative Distribution Function for African Americans 
The maximum likelihood estimates (MLE) for the Gamma probability distribution is 
given by the shape parameter,  ̂          and the scale parameter  ̂           The 
MLE for Weibull probability distribution is the shape parameter  ̂          and the 
scale parameter  ̂         . From the identified probability distribution function and 
their estimates, results of the basic statistics along with 90% and 95% confidence limits 
of the true malignant tumor size is given below in Table 2.2. 
Table 2.2 Fitted Distributions with Estimates and Confidence Intervals for African Americans 
Probability 
Distribution 
MLE 
Expected 
Value 
Standard 
Deviation 
90%  
C.I. 
95% 
 C.I. 
Gamma 
 ̂          
 ̂          
11.023 13.322 (0.17639, 37.82) (0.06382, 48.035) 
Weibull 
 ̂          
 ̂          
10.91 14.447 (0.19137, 39.082) (0.07601, 51.308) 
 
With respect to the probability distribution, we observed that the expected value of tumor 
size for Whites is larger than African Americans.  However, we proceed to formally test 
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if there is a statistical difference in the mean tumor size of Whites and African Americans 
in the next section. 
2.3 Comparison of Average Mean Tumor Sizes for Whites and African Americans 
We have identified the probability distribution functions that characterize the 
tumor size for Whites and African Americans. With large sample sizes, we invoke the 
central limit theorem (CLT) to compare the differences between the mean tumor sizes for 
these two races.  Using the following notations,              to represent the true 
population mean tumor sizes for Whites and African Americans, respectively, we 
compare the mean tumor sizes using two sample independent t-tests under the alternative 
hypothesis         . The samples mean tumor size and sample standard deviation 
under normality for Whites are 13.40 and 25.174, respectively, while African Americans 
are 11.02 and 15.152, respectively. A large p-value suggests that we fail to reject the null 
hypothesis, while a small p-value suggests that we reject the null hypothesis. Under our 
hypothesis, we reject the null hypothesis indicating that the mean tumor size for Whites is 
statistically larger than African Americans with a very small p-value. We also verified 
our decision nonparameterically using the Kruskal-Wallis test. The test results also 
showed that the mean tumor size for Whites is statistically larger than African Americans 
with a very small p-value. Thus, the results of both parametric and nonparametric tests 
are consistent. 
Under the assumption that the larger the tumor the higher the probability of it 
being malignant, we proceed to investigate the relationship between the probability of 
malignant tumor as a function of tumor size. 
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2.4 Malignancy of Tumor versus Tumor Size and Age 
2.4.1 Relationship between Malignant / Non-Malignant Tumor and Tumor Size 
One would expect that the size of a tumor should be related to the chance of the 
tumor being malignant. To better understand this relation, we proceed to construct the 
graph of the probability of malignant tumor given tumor size as a function of the size of 
tumor. The graph exhibiting this relationship is shown in Figure 2.4. 
 
Figure 2.4 Probability of Malignant Tumor as a function of Tumor Size 
In general, the graph appears to show an exponential growth between the size of a tumor 
and the chance of the tumor being malignant. At the one millimeter tumor size, there is a 
99.52% chance that the tumor would be malignant. We would be more certain that an 
individual with a tumor size of three millimeters and above to have an even higher 
chance for the tumor to be malignant. This aspect of the analysis suggests that the chance 
of a tumor being malignant would be higher in Whites than African Americans. 
However, the graph shows that an individual does not necessarily need to have a large 
tumor size for its tumor to be malignant. In other words, a small tumor size has a higher 
chance that the tumor would be malignant. 
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2.5 Malignant Tumor as a function of Age 
Prostate cancer is believed to usually occur in older men. From our database, we 
constructed a graph of the number of the patients with malignant tumor as a function of 
age. The graph is shown below in Figure 2.5.  
From the graph, it appears that the development of prostate cancer usually begin in men 
at the age of 36 years. However, it is very common in men at the age of 67. 
 
Figure 2.5 Number of Patients with Malignant Tumor as a function of Age 
2.6 Binomial Analysis 
In this analysis, our goal is to investigate if a larger tumor size increases the 
chance of getting prostate cancer. To formally address this question, we need to compute 
the conditional probability of a malignant tumor given the tumor size for Whites and 
African Americans. Next, we proceed to test the alternative hypothesis         .    
represents the proportion of Whites with malignant tumor given tumor size and      
represents the proportion of African Americans with malignant tumor given tumor size. 
The estimate of the proportion of Whites and African Americans with malignant tumor 
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given tumor size is 0.9985 and 0.9977, respectively.  The corresponding E(x)s for Whites 
and African Americans with malignant tumor given the tumor size are 22370.394 and 
22352.4708, respectively.  Under the one-sided hypothesis, we fail to reject the null 
hypothesis with a p-value of 0.25405 and conclude that there is no statistical difference 
between the proportion of Whites with malignant tumors given the tumor size and the 
proportion of African Americans with malignant tumors given the tumor size. In other 
words, the probability of developing prostate cancer is statistically the same for Whites 
and African Americans. 
This aspect of the analysis does not support the concept that African Americans 
are more likely to have prostate cancer than the Whites under the hypothesis that the 
larger the tumor the higher the probability of it being malignant.  
2.7 Conclusion 
In the parametric analysis, the probability distributions that characterize the 
malignant tumors for Whites and African Americans are obtained. Further, the 90% and 
95% confidence intervals are constructed based on the probability distribution that we 
have identified. This information provides the probabilistic behavior of malignant tumors 
for each race and also helps physicians to make informed decisions with some degrees of 
assurance.  
In addressing the question of differences in mean tumor size for prostate cancer, 
results show that the mean tumor size for Whites is statistically greater than African 
Americans. Thus, Whites tend to have a larger tumor size than African Americans.   
It is commonly understood that the risk of developing prostate cancer is higher in 
African American men than Whites. Results show that there is no statistical difference in 
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the proportion of Whites and African Americans with cancerous tumor given a tumor 
size. Thus, the chance of a tumor being cancerous is statistically the same for both races. 
Therefore, we have found that this concept is a “myth” and not a “reality”.  
Prostate cancer is believed to usually occur in older men. We have found that it mostly 
begins at the age of 36 and it’s very common in men at the age of 67. There is a high 
level of association between the size of a tumor and the level of the tumor being 
malignant. An individual with a one millimeter tumor size has a 99.52% chance that the 
tumor would be malignant. Also, with a three millimeter tumor size, we are almost 
certain that the tumor would be malignant. This indicates that to develop prostate cancer, 
one does not necessarily need to have a large tumor size. 
2.8 Contributions 
In the present chapter are answered some important questions concerning prostate 
cancer. 
 The appropriate probability distribution function that characterizes the behaviors 
of the malignant tumor sizes for white and African-American men. 
 The mean of cancerous tumor size for Whites is significant larger than African 
Americans. 
 There exists an exponential growth relationship between tumor size and the 
probability of the tumor being malignant. 
 The probability of developing prostate cancer between Whites and African 
Americans is statistically the same. 
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CHAPTER 3 PARAMETRIC SURVIVAL ANALYSIS FOR WHITES WITH 
PROSTATE CANCER 
The objective of the present study is to perform parametric survival analysis to 
compare the survivorship of prostate cancer patients for Whites by treatments (radiation 
therapy, surgery, combination of radiation and surgery, watchful waiting). In our 
analysis, we will first identify the existence of racial/ethnic disparities between white and 
African-American men using probabilistic analysis. We further examine the consistence 
of the stage of prostate cancer. Finally, we compare the survivorship for white men 
undergoing different treatment at each stage of prostate cancer. In addition, survival 
probability residual analysis is performed to evaluate the average difference in 
survivorship for white men under different treatments at a particular stage. 
3.1 Background and Data 
Prostate cancer treatments play an important role for patients when diagnosed 
with prostate cancer. This analysis is to investigate the most effective treatments for 
white men at each stage of prostate cancer. Data on the survival time of 23,714 
Adenocarcinoma prostate cancer patients for Whites and African Americans were 
obtained from the Surveillance Epidemiology and End Results (SEER) program. Out of 
23,714, approximately 91.6% are Whites and 8.4% are African Americans. Other 
variables considered are type of treatment and stage of prostate cancer. ‘Treatment’ is 
categorized as radiation only (Rad), surgery only (Surg), combination of radiation and 
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surgery (RadSurg), and no treatment (NoTreat). The stage of prostate cancer is coded ‘I’ 
for stage 1, ‘II’ for stage 2, ‘III’ for stage 3 and ‘IV’ for stage 4. ‘Censor’ is coded ‘0’ if 
the patient died before the end of the study and ‘1’ if the patient survived at the end of the 
study. It is worth mentioning that all recorded deaths in this study were due to prostate 
cancer. An extended detail of the dataset is given by Figure 3.1.   
 
Figure 3.1 Schematic Diagram of Prostate Cancer Patients by Race and the Stage of the Cancer. 
The survival times were calculated using the date of diagnosis and one of the following: 
date of death (i.e. if patient died before the end of the study), follow-up cutoff date (i.e. if 
the patient survived at the end of the study), or date last known to be alive. The follow-up 
cutoff date used in this study was December 31, 2008. 
3.2 Comparison and Evaluation of Survivorship by Race 
The best fitted probability distribution function that characterizes the behavior of 
the survival times for White men, African American men, and both races is the gamma 
distribution.  
Let   is a continuous random variable with probability density function (p.d.f.) 
     and cumulative distribution function (c.d.f.)             . 
Total 
(23,714) 
Whites 
(21,308) 
Stage I 
(8,066) 
Stage II 
(5,884) 
Stage III 
(5,643) 
Stage IV 
(1,715) 
African 
Americans 
(1,941) 
Stage I 
(827) 
Stage II 
(491) 
Stage III 
(409) 
Stage IV 
(214) 
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Under the gamma distribution, the survival function is defined as 
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where         is continuous shape parameter (   ), and   is continuous scale 
parameter (   ).   
The hazard function or instantaneous rate of occurrence of the event is defined as 
     
           
          
  
The approximate maximum likelihood estimates (MLE) and the corresponding estimated 
parametric survival and hazard functions for White men, African American men, and 
both races are shown in Table 3.1. 
A graphical display of the estimated survival functions are given by Figure 3.2. 
The graphs reveal that the estimated survival function for African American men is 
different from the combine race. However, the estimated survival function for White men 
appears to be approximately the same as the combined races.  
Table 3.1 Maximum Likelihood Estimates, Survival Functions, and Hazard Functions for All Stages by Race 
Race MLE Estimated Survival Function Estimated Hazard Function 
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Figure 3.2 Survival Function for All Stages by Race  
Based on these findings, we proceed to perform survival probability residual analysis by 
discretizing the time points. The difference between two survival curves at each time 
point is defined as the survival probability residuals. Let   ̂  represent the survival 
probability residual between combined races and White. That is: 
  ̂   ̂             ̂                        
While   ̂   represent the survival probability residual between combined races and 
African American. That is: 
  ̂    ̂             ̂                                   
The estimated mean probability residual between combined races and African Americans 
is approximately 0.0347 and between combined races and Whites is approximately -
0.0032. This indicates that making a decision for African Americans using the combined 
races is overestimated by approximately 3.47% while Whites is underestimated by 
approximately 0.32%. Furthermore, the average mean tumor for white men is statistically 
larger than African-American men (Y.M. Chan, 2012). Thus, it is essential to consider 
the survivorship of Whites and African Americans separately for efficient decision 
making. 
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3.3 Comparison and Evaluation of Survivorship by Stage 
The best fitted probability distribution function that characterizes the behavior of 
the survival times for stage I, II, III, and IV is the gamma distribution. The approximate 
maximum likelihood estimates (MLE) and the corresponding estimated parametric 
survival and hazard functions for Stage I, II, III, and IV are shown in Table 3.2.  
A graphical display of the estimated survival functions is given by Figure 3.3. The 
graphs reveal that the estimated survival function for stage I, II, III, and IV are different 
compared with all stage. The estimated mean probabilities of the residuals for stage I, II, 
III, and IV compared with all stages are approximately 2.37%, -1.07%, -5.79%, and 
10.17%, respectively. This reveals that making a decision using the combined stages is 
overestimated for stage I and IV while is underestimated for stage II and III. Thus, it is 
essential to identify the stage of the prostate cancer in order to make an efficient decision. 
Table 3.2 Maximum Likelihood Estimates, Survival Functions, and Hazard Functions for both Races by Stage 
Stage MLE Estimated Survival Function Estimated Hazard Function 
All Stage 
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Figure 3.3 Survival Function for both Races by Stage 
3.4 Comparison and Evaluation of Survivorship by Stage and Race 
The approximate maximum likelihood estimates (MLE) and the corresponding estimated 
parametric survival and hazard functions for White and African American men classified 
by stage of the prostate cancer are shown in Table 3.3.  
Figure 3.4 represents the survival functions for the four stages of prostate cancer 
for Whites and African Americans. The graphs reveal differences between Whites and 
African Americans in each stage of prostate cancer compared with both races. 
The estimated mean probabilities of the residuals for Whites in stage I, II, III, and 
IV compared with both race are approximately -0.23%, -0.22%, -0.21%, and -0.62%, 
respectively. On the other hand, the estimated mean probabilities of the residuals for 
African Americans in stage I, II, III, and IV compared with both races are approximately 
2.20%, 2.59%, 2.86%, and 4.69%, respectively. This reveals that making a decision using 
combined races in each stage is underestimated for White men while it is overestimated 
for African American men in each stage. Thus, it is essential to identify the stage of the 
prostate cancer and race of the patient in order to make an efficient decision. 
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Table 3.3 Maximum Likelihood Estimates, Survival Functions, and Hazard Functions by the Stage of the Cancer and Race  
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Figure 3.4 Survival Function by the Stage of the Prostate Cancer and Race 
3.5 Comparison of Survivorship for White men by Stage and Treatment 
A patient at each stage is subject to no treatment, radiation therapy, surgery, and 
combination of radiation and surgery. A network diagram of the prostate cancer data for 
each state is given by Figure 3.5. 
 
Figure 3.5 A Network Diagram of Different Treatments 
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 3.5.1 Stage I: Evaluation of Survivorship for Whites by Treatment 
Case 0: No Treatment (Watchful Waiting) 
In order to perform the parametric survival analysis, we need to identify 
appropriate probability distribution function that characterizes the behavior of the 
survival times. Different classical distributions were fitted to the observed data. The 
observed survival times follow a two parameter gamma distribution.  
The two parameter gamma probability distribution function with shape parameter   and 
location parameter   is given by:  
         
        
    
           
                         ∫          
 
 
    
The corresponding survival function is given by:  
              ∫       
 
 
   
  (  
 
 )
    
   
where         ∫  
        
 
 
 is the lower incomplete gamma function and the hazard 
function given by: 
     
    
      
 
       
          
   
           is the cumulative density function of     . The survival function has no 
closed-form expression. However, there exist algorithms for its computation.  
The approximate maximum likelihood estimates (MLE) for White men under 
watchful waiting are  ̂         and   ̂         [20]. From the identified probability 
distribution function and their estimates, the E(x), median, and 95% confidence limits of 
the survival time of a given prostate cancer patient from such a population are 7.99, 7.17, 
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and (1.76, 18.84), respectively. The analytical form of the survival function      with the 
MLE is given by: 
              ∫       
 
 
   
  (  
 
 )
    
  
With the maximum likelihood estimates, the survival function can be reduced to 
       
  (       
 
      )
         
  
The graphical form is given by Figure 3.6. 
 
Figure 3.6 Stage I: Survival Function for Whites under watchful waiting 
Notice that the time t=0 year: patients were diagnosed with prostate cancer and under 
watchful waiting. Thus, a physician could be able to answer questions from a patient 
under watchful waiting; the probability of the patient will survive in 10 years is 
approximately 30%. Also, the probability of a given patient that will survive the expected 
survival time of 8 years is approximately 37%. 
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Case I: Radiation Therapy 
The best fitted probability distribution function that characterizes the behavior of 
the survival times in Stage I for White men receiving radiation therapy was the gamma 
distribution. The approximate maximum likelihood estimates (MLE) for White men 
receiving radiation therapy are  ̂         and  ̂        [20]. From the identified 
probability distribution function and their estimates, the E(x), median, and 95% 
confidence limits of the survival time of a given prostate cancer patient from such as 
population are 9.27, 8.65 and (2.99, 19.04), respectively. The analytical form of the 
survival function      with the MLE is given by: 
              ∫       
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With the maximum likelihood estimates, the survival function can be reduced to 
       
  (       
 
     )
         
  
The graphical form is given by Figure 3.7. 
 
Figure 3.7 Stage I: Survival Function for Whites receiving Radiation Therapy 
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Notice that the time t=0 year: patients were diagnosed with prostate cancer and proceed 
with radiation therapy. Thus, a physician could be able to answer questions from a patient 
after radiation therapy; the probability of the patient will survive in 10 years is 
approximately 38%. Also, the probability of a given patient that will survive the expected 
survival time of 9.3 years is approximately 40%. 
Case II: Surgery 
The best fitted probability distribution function that characterizes the behavior of 
the survival times in Stage I for White men undergoing surgery was the gamma 
distribution with the approximate maximum likelihood estimates  ̂        and  ̂  
      . The corresponding E(x), median, and 95% confident limit are 9.57, 8.66, and 
(2.25, 22.10), respectively.  The analytical form of the survival function      with the 
MLE is given by: 
              ∫       
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With the maximum likelihood estimates, the survival function can be reduced to 
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The graphical form is given by Figure 3.8. 
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Figure 3.8 Stage I: Survival Function for Whites undergoing Surgery 
Notice that the time t=0 year: patients were diagnosed with prostate cancer and proceed 
with surgery. Thus, a physician could be able to answer questions from a patient after 
surgery; the probability of the patient will survive in 10 years is approximately 41%. 
Also, the probability of a given patient that will survive the expected survival time of 9.6 
years is approximately 42%. 
Case III: Combination of Radiation and Surgery 
The best fitted probability distribution function that characterizes the behavior of the 
survival times in Stage I for White men undergoing surgery and radiation therapy was the 
gamma distribution with the approximate maximum likelihood estimates  ̂         and 
 ̂        . The corresponding E(x), median, and 95% confident limit are 9.92, 9.12, 
and (2.75, 21.61), respectively.  The analytical form of the survival function      with the 
MLE is given by: 
              ∫       
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With the maximum likelihood estimates, the survival function can be reduced to 
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  (       
 
      )
         
  
The graphical form is given by Figure 3.9. 
 
Figure 3.9 Stage I: Survival Function for Whites receiving both Surgery and Radiation Therapy 
Notice that the time t=0 year: patients were diagnosed with prostate cancer and proceed 
with both surgery and radiation. Thus, a physician could be able to answer questions from 
a patient after both surgery and radiation therapy; the probability of the patient will 
survive in 10 years is approximately 45%. Also, the probability of a given patient that 
will survive the expected survival time of 9.9 years is approximately 45%. 
Combined the results, a graphical display of the survival functions for white men 
undergoing different treatment of prostate cancer is given by Figure 3.10. 
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Figure 3.10 Stage I: Survival Function for Whites by Treatment 
 
Table 3.4 Survival Probability for Whites in Stage I by Treatment 
  Survival Probability 
Time in Year NT Rad Surg Comb 
1 0.9948 0.9997 0.9978 0.9993 
2 0.9649 0.9948 0.9822 0.9913 
3 0.9041 0.9746 0.9455 0.9669 
4 0.8190 0.9308 0.8879 0.9219 
5 0.7198 0.8618 0.8140 0.8572 
6 0.6164 0.7725 0.7300 0.7778 
7 0.5164 0.6712 0.6419 0.6897 
8 0.4245 0.5665 0.5548 0.5989 
9 0.3433 0.4659 0.4723 0.5104 
10 0.2739 0.3742 0.3967 0.4277 
11 0.2158 0.2944 0.3293 0.3531 
12 0.1683 0.2273 0.2705 0.2876 
13 0.1300 0.1726 0.2201 0.2315 
14 0.0996 0.1292 0.1776 0.1843 
15 0.0757 0.0954 0.1423 0.1453 
16 0.0572 0.0695 0.1132 0.1136 
17 0.0429 0.0502 0.0895 0.0881 
18 0.0321 0.0358 0.0703 0.0678 
19 0.0238 0.0254 0.0550 0.0518 
20 0.0176 0.0178 0.0428 0.0394 
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Figure 3.10 shows that patients receiving radiation therapy, surgery, or combination of 
radiation and surgery have better survivorship than the patients under watchful waiting. 
However, it could not distinguish the survivorship among the three types of treatments. 
We proceed to evaluate survival probability in different treatment by discretizing the time 
points and the results are shown in Table 3.4.  
In determining the treatment response for each year, we performed a pairwise comparison 
between two treatments at each time point is defined as the survival probability residuals. 
Let   ̂     represent the survival probability residual between no treatment and radiation 
therapy: 
  ̂      ̂        ̂                      
  ̂      represents the survival probability residual between no treatment and surgery. 
That is: 
  ̂       ̂        ̂                       
  ̂      represents the survival probability residual between no treatment and 
combination of radiation and surgery. That is: 
  ̂       ̂        ̂                       
  ̂       represents the survival probability residual between radiation therapy and 
surgery. That is: 
  ̂        ̂         ̂                       
  ̂       represents the survival probability residual between radiation therapy and 
combination of radiation and surgery. That is:  
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  ̂        ̂         ̂                       
  ̂        represents the survival probability residual between surgery and combination 
of radiation and surgery. That is: 
  ̂         ̂          ̂                       
The estimated mean probability residual between watchful waiting and radiation therapy 
is approximately -0.065, between watchful waiting and surgery is approximately -0.075, 
and between watchful waiting and combination of radiation and surgery is approximately 
-0.093, between radiation therapy and surgery is approximately -0.010, between radiation 
therapy and combination of radiation and surgery is approximately -0.029, and between 
surgery and combination of radiation and surgery is approximately -0.019. A series of 
hypothesis tests was performed to compare the significant differences between two 
treatments. The results were found significant between watchful waiting and radiation 
therapy (p < 0.0001), between watchful waiting and surgery (p < 0.0001), between 
watchful waiting and combination of radiation and surgery (p < 0.0001), between 
radiation therapy and combination of radiation and surgery (p < 0.0001), and between 
surgery and combination of radiation and surgery (p < 0.0001). However, it is not 
significant between radiation therapy and surgery (p = 0.2). The nonparametric test also 
verified our decision and the results are consistent.  
3.5.2 Stage II: Evaluation of Survivorship for Whites by Treatment 
Case 0: No Treatment (Watchful Waiting) 
The best fitted probability distribution function that characterizes the behavior of 
the survival times in Stage II for White men under watchful waiting was the gamma 
distribution. The approximate maximum likelihood estimates (MLE) for White men 
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under watchful waiting are  ̂         and  ̂        . From the identified probability 
distribution function and their estimates, the E(x), median, and 95% confidence limits of 
the survival time of a given prostate cancer patient from such as population are 7.31, 
6.54, and (1.56, 17.43) respectively. The analytical form of the survival function      
with the MLE is given by: 
              ∫       
 
 
   
  (  
 
 )
    
  
With the maximum likelihood estimates, the survival function can be reduced to 
       
  (       
 
      )
         
  
Its graphical form is given by Figure 3.11. 
 
Figure 3.11 Stage II: Survival Function for Whites under watchful waiting 
Notice that the time t=0 year: patients were diagnosed with prostate cancer under 
watchful waiting. Thus, a physician could be able to answer questions from a patient 
under watchful waiting; the probability of the patient will survive in 10 years is 
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approximately 22%. Also, the probability of a given a patient that will survive the 
expected survival time of 7.3 years is approximately 35%. 
Case I: Radiation Therapy 
The best fitted probability distribution function that characterizes the behavior of 
the survival times in Stage II for White men receiving radiation therapy was the gamma 
distribution. The approximate maximum likelihood estimates (MLE) for White men 
receiving radiation therapy are  ̂         and  ̂        . From the identified 
probability distribution function and their estimates, the E(x), median, and 95% 
confidence limits of the survival time of a given prostate cancer patient from such as 
population are 9.17, 8.44, and (2.55, 19.95), respectively. The analytical form of the 
survival function      with the MLE is given by: 
              ∫       
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With the maximum likelihood estimates, the survival function can be reduced to 
       
  (       
 
      )
         
  
Its graphical form is given by Figure 3.12. 
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Figure 3.12 Stage II: Survival Function for Whites receiving Radiation Therapy 
Notice that the time t=0 year: patients were diagnosed with prostate cancer and proceed 
with radiation therapy. Thus, a physician could be able to answer questions from a patient 
after radiation therapy; the probability of the patient will survive in 10 years is 
approximately 38%. Also, the probability of a given a patient that will survive the 
expected survival time of 9 years is approximately 39%. 
Case II: Surgery 
The best fitted probability distribution function that characterizes the behavior of 
the survival times in Stage II for White men undergoing surgery was the gamma 
distribution with approximate maximum likelihood estimates  ̂         and  ̂  
      . The corresponding E(x), median, and 95% confident limit are 10.44, 9.71, and 
(3.23, 21.80), respectively.  The analytical form of the survival function      with the 
MLE is given by: 
              ∫       
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With the maximum likelihood estimates, the survival function can be reduced to 
20151050
1.0
0.8
0.6
0.4
0.2
0.0
Time in Year
S
u
rv
iv
a
l P
ro
b
a
b
ili
ty
Survival Function for Whites receiving Radiation Therapy in Stage II
45 
 
       
  (       
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Its graphical form is given by Figure 3.13. 
 
Figure 3.13 Stage II: Survival Function for Whites undergoing Surgery 
Notice that the time t=0 year: patients were diagnosed with prostate cancer and proceed 
with surgery. Thus, a physician could be able to answer a question from a patient after 
surgery; the probability of the patient will survive in 10 years is approximately 50%, 
which is same as the probability of a given a patient that will survive the expected 
survival time. 
Case III: Combination of Radiation and Surgery 
The best fitted probability distribution function that characterizes the behavior of 
the survival times in Stage II for White men receiving both radiation therapy and surgery 
was the gamma distribution with approximate maximum likelihood estimates  ̂         
and  ̂        . The corresponding E(x), median, and 95% confident limit are 10.92, 
10.13, and (3.32, 22.95) respectively.  The analytical form of the survival function      
with the MLE is given by: 
20151050
1.0
0.8
0.6
0.4
0.2
0.0
Time in Year
S
u
rv
iv
a
l 
P
ro
b
a
b
ili
ty
Survival Function for Whites undergoing Surgery in Stage II
46 
 
              ∫       
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With the maximum likelihood estimates, the survival function can be reduced to 
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Its graphical form is given by Figure 3.14. 
 
Figure 3.14 Stage II: Survival Function for Whites receiving both Surgery and Radiation Therapy 
Notice that the time t=0 year: patients were diagnosed with prostate cancer and proceed 
with both surgery and radiation. Thus, a physician could be able to answer a question 
from a patient after both surgery and radiation; the probability of the patient will survive 
in 10 years is approximately 55%. Also, the probability of a given a patient that will 
survive the expected survival time of 11 years is approximately 56%. 
Combined these cases, a graphical display of the survival functions for white men 
undergoing different treatment of prostate cancer is given by Figure 3.15. 
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Figure 3.15 Stage II: Survival Function for Whites by Treatments 
It appears patients undergoing surgery or combination of radiation and surgery have 
better survivorship than the patients receiving radiation therapy or under watchful 
waiting. Also, patients have higher survivorship in receiving radiation therapy than under 
watchful waiting. However, it could not distinguish the differences in survivorship 
between surgery and combination of radiation and surgery. We proceed to evaluate 
survival probability in different treatment by discretizing the time points and the results 
are shown in Table 3.5.  
In determining the treatment response for each year, we performed a pairwise 
comparison between two treatments at each time point is defined as the survival 
probability residuals. The estimated mean probability residual between watchful waiting 
and radiation therapy is approximately -0.091, between watchful waiting and surgery is 
approximately -0.152, and between watchful waiting and combination of radiation and 
surgery is approximately -0.173, between radiation therapy and surgery is approximately 
-0.061, between radiation therapy and combination of radiation and surgery is 
approximately -0.082, and between surgery and combination of radiation and surgery is 
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approximately -0.021. A series of hypothesis tests was performed to compare the 
significant differences between two treatments. The results were found significant 
between watchful waiting and radiation therapy (p < 0.0001), between watchful waiting 
and surgery (p < 0.0001), between watchful waiting and combination of radiation and 
surgery (p < 0.0001), between radiation therapy and surgery (p < 0.0001), between 
radiation therapy and combination of radiation and surgery (p < 0.0001), and between 
surgery and combination of radiation and surgery (p < 0.0001). The nonparametric test 
also verified our decision and the results are consistent. 
Table 3.5 Survival Probability for Whites in Stage II by Treatment 
  Survival Probability 
Time in Year NT Rad Surg Comb 
1 0.9924 0.9991 0.9998 0.9998 
2 0.9526 0.9889 0.9959 0.9962 
3 0.8774 0.9585 0.9809 0.9825 
4 0.7777 0.9037 0.9483 0.9530 
5 0.6671 0.8274 0.8959 0.9056 
6 0.5566 0.7365 0.8258 0.8417 
7 0.4539 0.6389 0.7430 0.7653 
8 0.3630 0.5414 0.6534 0.6815 
9 0.2856 0.4495 0.5626 0.5953 
10 0.2216 0.3665 0.4752 0.5108 
11 0.1698 0.2940 0.3944 0.4313 
12 0.1288 0.2325 0.3223 0.3589 
13 0.0968 0.1815 0.2596 0.2948 
14 0.0721 0.1401 0.2065 0.2392 
15 0.0534 0.1070 0.1624 0.1920 
16 0.0392 0.0810 0.1263 0.1526 
17 0.0287 0.0608 0.0973 0.1202 
18 0.0208 0.0453 0.0744 0.0939 
19 0.0151 0.0335 0.0563 0.0728 
20 0.0108 0.0246 0.0424 0.0560 
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3.5.3 Stage III: Evaluation of Survivorship for Whites by Treatment 
Case 0: No Treatment (Watchful Waiting) 
The best fitted probability distribution function that characterizes the behavior of 
the survival times in Stage III for White men under watchful waiting was the gamma 
distribution. The approximate maximum likelihood estimates (MLE) for White men 
under watchful waiting are  ̂        and  ̂        . From the identified probability 
distribution function and their estimates, the E(x), median, and 95% confidence limits of 
the survival time of a given prostate cancer patient from such a population are 6.65, 5.55, 
and (0.76, 18.75), respectively. The analytical form of the survival function      with the 
MLE is given by: 
              ∫       
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With the maximum likelihood estimates, the survival function can be reduced to 
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The graphical form is given by Figure 3.16. 
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Figure 3.16 Stage III: Survival Function for Whites under watchful waiting 
Notice that the time t=0 year: patients were diagnosed with prostate cancer and under 
watchful waiting. Thus, a physician could be able to answer questions from a patient 
under watchful waiting; the probability of the patient will survive in 10 years is 
approximately 20%. Also, the probability of a given a patient that will survive the 
expected survival time of 6.6 years is approximately 42%. 
Case I: Radiation Therapy 
The best fitted probability distribution function that characterizes the behavior of 
the survival times in Stage III for White men receiving radiation therapy was the gamma 
distribution. The approximate maximum likelihood estimates (MLE) for White men are 
 ̂         and  ̂        . The corresponding E(x), median, and 95% confidence 
limits of the survival time is 8.83, 7.94, and (1.99, 20.67), respectively. The analytical 
form of the survival function      with the MLE is given by 
              ∫       
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With the maximum likelihood estimates, the survival function can be reduced to 
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The graphical form is given by Figure 3.17. 
 
Figure 3.17 Stage III: Survival Function for Whites receiving Radiation Therapy 
Notice that the time t=0 year: patients were diagnosed with prostate cancer and proceed 
with radiation therapy. Thus, a physician could be able to answer questions from a patient 
after radiation therapy; the probability of the patient will survive in 10 years is 
approximately 36%. Also, the probability of a given a patient that will survive the 
expected survival time of 9 years is approximately 40%. 
Case II: Surgery 
The best fitted probability distribution function that characterizes the behavior of 
the survival times in Stage III for White men undergoing surgery was the gamma 
distribution with approximate maximum likelihood estimates  ̂        and  ̂       . 
The corresponding E(x), median, and 95% confident limit are 11.39, 10.81, and (4.38, 
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21.70), respectively. The analytical form of the survival function      with the MLE is 
given by: 
              ∫       
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With the maximum likelihood estimates, the survival function can be reduced to 
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The graphical form is given by Figure 3.18. 
 
Figure 3.18 Stage III: Survival Function for Whites undergoing Surgery 
Notice that the time t=0 year: patients were diagnosed with prostate cancer and proceed 
with surgery. Thus, a physician could be able to answer questions from a patient after 
surgery; the probability of the patient will survive in 10 years is approximately 60%. 
Also, the probability of a given a patient that will survive the expected survival time of 
11 years is approximately 50%. 
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Case III: Combination of Radiation and Surgery 
The best fitted probability distribution function that characterizes the behavior of 
the survival times in Stage III for White men receiving both radiation therapy and surgery 
was the gamma distribution with approximate maximum likelihood estimates  ̂         
and  ̂        . The corresponding E(x), median, and 95% confident limit are 11.08, 
10.42, and (3.86, 22.05), respectively. The analytical form of the survival function      
with the MLE is given by: 
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With the maximum likelihood estimates, the survival function can be reduced to 
       
  (       
 
      )
         
  
The graphical form is given by Figure 3.19. 
 
Figure 3.19 Stage III: Survival Function for Whites receiving both Surgery and Radiation Therapy 
Notice that the time t=0 year: patients were diagnosed with prostate cancer and proceed 
with surgery and radiation. Thus, a physician could be able to answer questions from a 
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patient after both surgery and radiation therapy; the probability of the patient will survive 
in 10 years is approximately 55%. Also, the probability of a given a patient that will 
survive the expected survival time of 11 years is approximately 45%. 
Combined these cases, a graphical display of the survival functions for white men 
undergoing different treatment of prostate cancer is given by Figure 3.20. 
 
Figure 3.20 Stage III: Survival Function for Whites by Treatments 
Figure 3.20 revealed that patients undergoing surgery or combination of radiation and 
surgery have better survivorship than the patients receiving radiation therapy or under 
watchful waiting. Also, patients have higher survivorship in receiving radiation therapy 
than the patients under watchful waiting. However, it could not distinguish the 
differences in survivorship between surgery and combination of radiation and surgery. 
We proceed to evaluate survival probability in different treatment by discretizing the time 
points and the results are shown in Table 3.6.  
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Table 3.6 Survival Probability for Whites in Stage III by Treatment 
  Survival Probability 
Time in Year NT Rad Surg Comb 
1 0.9599 0.9965 1.0000 1.0000 
2 0.8722 0.9745 0.9995 0.9986 
3 0.7657 0.9271 0.9959 0.9912 
4 0.6563 0.8570 0.9834 0.9713 
5 0.5527 0.7716 0.9560 0.9337 
6 0.4591 0.6785 0.9095 0.8773 
7 0.3773 0.5847 0.8440 0.8044 
8 0.3073 0.4950 0.7628 0.7197 
9 0.2485 0.4126 0.6714 0.6289 
10 0.1997 0.3394 0.5763 0.5377 
11 0.1596 0.2760 0.4829 0.4505 
12 0.1270 0.2220 0.3959 0.3705 
13 0.1007 0.1770 0.3180 0.2996 
14 0.0795 0.1400 0.2507 0.2385 
15 0.0626 0.1099 0.1943 0.1873 
16 0.0492 0.0857 0.1483 0.1452 
17 0.0385 0.0665 0.1116 0.1112 
18 0.0301 0.0512 0.0828 0.0843 
19 0.0235 0.0393 0.0608 0.0632 
20 0.0183 0.0300 0.0441 0.0470 
 
The estimated mean probability residual between watchful waiting and radiation therapy 
is approximately -0.107, between watchful waiting and surgery is approximately -0.235, 
and between watchful waiting and combination of radiation and surgery is approximately 
-0.219, between radiation therapy and surgery is approximately -0.128, between radiation 
therapy and combination of radiation and surgery is approximately -0.111, and between 
surgery and combination of radiation and surgery is approximately 0.016. A series of 
hypothesis tests was performed to compare the significant differences between two 
treatments. The results were found significant between watchful waiting and radiation 
therapy (p < 0.0001), between watchful waiting and surgery (p < 0.0001), between 
watchful waiting and combination of radiation and surgery (p < 0.0001), between 
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radiation therapy and surgery (p < 0.0001), between radiation therapy and combination of 
radiation and surgery (p < 0.0001), and between surgery and combination of radiation 
and surgery (p < 0.0001). The nonparametric test also verified our decision and the 
results are consistent.  
3.5.4 Stage IV: Evaluation of Survivorship for Whites by Treatment 
Case 0 No Treatment (Watchful Waiting) 
The best fitted probability distribution function that characterizes the behavior of 
the survival times in Stage IV for White men under watchful waiting was the gamma 
distribution. The approximate maximum likelihood estimates (MLE) for White men 
under watchful waiting are  ̂         and  ̂        . From the identified probability 
distribution function and their estimates, the E(x), median, and 95% confidence limits of 
the survival time of a given prostate cancer patient from such a population are 4.57, 3.43, 
and (0.22, 15.28), respectively. The analytical form of the survival function      with the 
MLE is given by: 
              ∫       
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With the maximum likelihood estimates, the survival function can be reduced to 
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The graphical form is given by Figure 3.21. 
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Figure 3.21 Stage IV: Survival Function for Whites under watchful waiting 
Notice that the time t=0 year: patients were diagnosed with prostate cancer and under 
watchful waiting. Thus, a physician could be able to answer questions from a patient 
under watchful waiting; the probability of the patient will survive in 10 years is 
approximately 10%. Also, the probability of a given a patient that will survive the 
expected survival time of 5 years is approximately 36%. 
Case I: Radiation Therapy 
The best fitted probability distribution function that characterizes the behavior of 
the survival times in Stage IV for White men receiving radiation therapy was the gamma 
distribution. The approximate maximum likelihood estimates (MLE) for White men are 
 ̂         and  ̂        . The corresponding E(x), median, and 95% confidence 
limits of the survival time of a given prostate cancer patient from such a population are 
6.75, 5.61, and (0.75, 19.21), respectively. The analytical form of the survival function 
     with the MLE is given by: 
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With the maximum likelihood estimates, the survival function can be reduced to 
       
  (       
 
      )
         
  
The graphical form is given by Figure 3.22. 
 
Figure 3.22 Stage IV: Survival Function for Whites receiving Radiation Therapy 
Notice that the time t=0 year: patients were diagnosed with prostate cancer and proceed 
with radiation therapy. Thus, a physician could be able to answer questions from a patient 
after radiation therapy; the probability of the patient will survive in 10 years is 
approximately 20%. Also, the probability of a given a patient that will survive the 
expected survival time of 7 years is approximately 40%. 
Case II: Surgery 
The best fitted probability distribution function that characterizes the behavior of 
the survival times in Stage IV for White men undergoing surgery was the gamma 
distribution with approximate maximum likelihood estimates  ̂         and  ̂  
      . The corresponding E(x), median, and 95% confident limit are 8.12, 7.30, and 
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(1.83, 18.96), respectively. The analytical form of the survival function      with the 
MLE is given by: 
              ∫       
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With the maximum likelihood estimates, the survival function can be reduced to 
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The graphical form is given by Figure 3.23. 
 
Figure 3.23 Stage IV: Survival Function for Whites undergoing Surgery 
Notice that the time t=0 year: patients were diagnosed with prostate cancer and proceed 
with surgery. Thus, a physician could be able to answer questions from a patient after 
surgery; the probability of the patient will survive in 10 years is approximately 25%. 
Also, the probability of a given a patient that will survive the expected survival time of 8 
years is approximately 42%. 
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Case III: Combination of Radiation and Surgery 
The best fitted probability distribution function that characterizes the behavior of 
the survival times in Stage IV for White men receiving both radiation therapy and surgery 
was the gamma distribution with approximate maximum likelihood estimates  ̂         
and  ̂       . The corresponding E(x), median, and 95% confident limit are 8.70, 7.77, 
and (1.83, 20.82), respectively. The analytical form of the survival function      with the 
MLE is given by: 
              ∫       
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With the maximum likelihood estimates, the survival function can be reduced to 
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The graphical form is given by Figure 3.24. 
 
Figure 3.24 Stage IV: Survival Function for Whites receiving both Surgery and Radiation Therapy 
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Notice that the time t=0 year: patients were diagnosed with prostate cancer and proceed 
with surgery and radiation. Thus, a physician could be able to answer questions from a 
patient after surgery and radiation therapy; the probability of the patient will survive in 10 
years is approximately 33%. Also, the probability of a given a patient that will survive 
the expected survival time of 9 years is approximately 40%. 
From the cases in stage IV, a graphical display of the survival functions for white 
men undergoing different treatment of prostate cancer is given by Figure 3.25. 
 
Figure 3.25 Stage IV: Survival Function for Whites by Treatments 
It shows that patients undergoing surgery or combination of radiation and surgery have 
better survivorship than the patients receiving radiation therapy or under watchful 
waiting. Also, patients have higher survivorship in receiving radiation therapy than the 
patients under watchful waiting. However, it could not distinguish the differences in 
survivorship between surgery and combination of radiation and surgery. We proceed to 
evaluate survival probability in different treatment by discretizing the time points and the 
results are shown in Table 3.7. 
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Table 3.7: Survival Probability for Whites in Stage IV by Treatment 
  Survival Probability 
Time in Year NT Rad Surg Comb 
1 0.8512 0.9585 0.9956 0.9951 
2 0.6916 0.8710 0.9683 0.9685 
3 0.5526 0.7660 0.9110 0.9156 
4 0.4374 0.6586 0.8288 0.8414 
5 0.3440 0.5570 0.7315 0.7537 
6 0.2693 0.4650 0.6288 0.6605 
7 0.2100 0.3843 0.5285 0.5679 
8 0.1634 0.3150 0.4357 0.4804 
9 0.1268 0.2565 0.3533 0.4007 
10 0.0982 0.2076 0.2823 0.3302 
11 0.0760 0.1672 0.2229 0.2692 
12 0.0587 0.1341 0.1740 0.2174 
13 0.0453 0.1071 0.1345 0.1741 
14 0.0349 0.0853 0.1031 0.1384 
15 0.0269 0.0677 0.0784 0.1094 
16 0.0207 0.0536 0.0593 0.0859 
17 0.0159 0.0424 0.0445 0.0670 
18 0.0122 0.0334 0.0332 0.0521 
19 0.0094 0.0263 0.0247 0.0403 
20 0.0072 0.0207 0.0182 0.0311 
 
The estimated mean probability residual between watchful waiting and radiation therapy 
is approximately -0.106, between watchful waiting and surgery is approximately -0.175, 
and between watchful waiting and combination of radiation and surgery is approximately 
-0.202, between radiation therapy and surgery is approximately -0.069, between radiation 
therapy and combination of radiation and surgery is approximately -0.096, and between 
surgery and combination of radiation and surgery is approximately -0.027. A series of 
hypothesis tests was performed to compare the significant differences between two 
treatments. The results were found significant between watchful waiting and radiation 
therapy (p < 0.0001), between watchful waiting and surgery (p < 0.0001), between 
watchful waiting and combination of radiation and surgery (p < 0.0001), between 
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radiation therapy and surgery (p < 0.0001), between radiation therapy and combination of 
radiation and surgery (p < 0.0001), and between surgery and combination of radiation 
and surgery (p < 0.0001). The nonparametric test also verified our decision and the 
results are consistent.  
3.6 Conclusions 
In this present study, we can conclude that the average difference in survivorship 
of combined races is approximately 3.47% higher than African Americans. Also, the 
average differences in survivorship for all four stages compared with stage I, III, and IV 
are 2.37%, 5.79%, and 10.17%, respectively. Furthermore, the average differences in 
survival of African American men compared with both races in stage I, II, III, and IV are 
2.20%, 2.59%, 2.86%, and 4.69%, respectively. These results reveal the existence of 
heterogeneity among race and the stage of the prostate cancer. Thus, in prostate cancer 
statistical analysis, it is essential to stratify by stage and race in order to make efficient 
decisions. 
In stage I, White men have a better survival receiving radiation therapy, surgery, 
and combination of radiation and surgery than under watchful waiting. The 
corresponding estimated mean probability residual are 6.5%, 7.5%, and 9.3%, 
respectively. Moreover, the survivorship of White men undergoing combination of 
radiation and surgery is better than undergoing surgery and radiation therapy. The 
corresponding estimated mean probabilities residual are 1.9% and 2.9%. However, the 
survivorship of radiation therapy and surgery are approximately the same under 5% level 
of significance. 
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In stage II, White men have a better survival receiving radiation therapy, surgery 
and combination of radiation surgery than under watchful waiting. The corresponding 
estimated mean probability residual are 9.1 %, 15.2%, and 17.3%, respectively. 
Moreover, the survivorship of White men undergoing combination of radiation and 
surgery are better than receiving radiation therapy and undergoing surgery. The 
corresponding estimated mean probabilities residual are 8.2 %, 2.1%, respectively. Also, 
the survivorship of surgery is better than radiation therapy with the estimated mean 
probability residual of 6.1%. 
In stage III, White men have a better survival receiving radiation therapy, surgery 
and combination of radiation surgery than under watchful waiting. The corresponding 
estimated mean probability residual are 10.7%, 23.5%, and 21.9%, respectively. 
Moreover, the survivorship of White men undergoing surgery is better than receiving 
radiation therapy and undergoing combination of radiation and surgery. The 
corresponding estimated mean probabilities residual are 12.8%, 1.6%, respectively. Also, 
the survivorship of combination of radiation and surgery is better than radiation therapy 
with the estimated mean probability residual of 11.1%. 
In stage IV, White men have a better survival receiving radiation therapy, surgery 
and combination of radiation surgery than under watchful waiting. The corresponding 
estimated mean probability residual are 10.6%, 17.5%, and 20.2%, respectively. 
Moreover, the survivorship of White men undergoing combination of radiation and 
surgery are better than receiving radiation therapy and undergoing surgery. The 
corresponding estimated mean probabilities residual are 9.6% and 2.7%, respectively. 
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Also, the survivorship of surgery is better than radiation therapy with the estimated mean 
probability residual of 6.9%. 
These findings will help physicians give an estimate of the survivorship for White 
men under different treatment at the four different stages of prostate cancer, and provide 
an appropriate cost-effect treatment for patients depending on the stage of prostate 
cancer. 
3.7 Contributions 
In the present chapter are answered some important questions concerning prostate 
cancer. 
 The best fitted probability distribution function that characterizes the behavior of 
the survival times for Whites and African Americans is gamma distribution. 
 It is important to consider racial/ethnic disparities in order to improve the analysis 
and make better decisions. 
 The four stages of prostate cancer are shown to be consistent. Thus, it is essential 
to perform analysis at each stage of prostate cancer. 
 We have identified the estimated mean probability residual of Whites undergoing 
different treatments at a particular stage of prostate cancer. These findings will 
help physicians provide an appropriate prostate cancer treatment and cost-
effective strategies for the patients in order to maximize the survival rate and 
minimize the treatment costs. 
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CHAPTER 4 PARAMETRIC SURVIVAL MODELING FOR WHITES WITH 
PROSTATE CANCER 
The objective of the present study is to perform parametric survival modeling to 
compare the survivorship of prostate cancer patients for Whites by treatments (radiation 
therapy, surgery, combination of radiation and surgery, watchful waiting). In our 
modeling, we consider the risk factors (age at diagnosis, tumor size, and interaction 
between age at diagnosis and tumor size).  We further estimate the survival time from the 
parametric survival model. Finally, we compare the survivorship for white men by 
treatment in the four different stages of prostate cancer. In addition, survival probability 
residual analysis is performed to evaluate the average difference in survivorship for white 
men under different treatments at a particular stage.
4.1 Background and Data 
Existed research had identified that age at diagnosis was a significant risk factor 
for prostate cancer. Lin et al. revealed that younger men were more like to undergo 
prostatectomy to have better survival at 10 years compared with older men (Daniel W. 
Lin, 2009). Also, older men were more frequently to be diagnosed with high-risk prostate 
cancer and to have lower survival rate (Ketchandji M, 2009; Konety BR, 2008; Manton 
KG, 1995; Richstone L, 2008). The size of tumor is also a high risk factor for prostate 
cancer. Research had shown that tumor growth rate was correlated to survival time 
(Wilfred D. Stein, 2010). However, little is known about how the interaction between age 
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at diagnosis and tumor size affect to the survival time. Thus, we performed the parametric 
regression modeling for white men at each stage of prostate cancer receiving different 
treatment with the predictors (age at diagnosis, tumor size, and the interaction between 
age at diagnosis and tumor size).  
In order to perform the parametric regression analysis, we need to identify an 
appropriate probability distribution function that characterizes the behavior of the 
survival times. In chapter 3, we revealed that a gamma distribution was the appropriate 
probability distribution function that characterizes the behavior of the survival times. 
Data on the survival time of 21,308 Adenocarcinoma prostate cancer patients for Whites 
were obtained from the Surveillance Epidemiology and End Results (SEER) program. 
Other variables considered are type of treatment, stage of prostate cancer, age at 
diagnosis, and tumor size. ‘Treatment’ is categorized as radiation only (Rad), surgery 
only (Surg), combination of radiation and surgery (RadSurg), and no treatment 
(NoTreat). The stage of prostate cancer is coded ‘I’ for stage 1, ‘II’ for stage 2, ‘III’ for 
stage 3 and ‘IV’ for stage 4. Age at diagnosis was collapsed into eleven groups: age of 
36-40 (=0), 41-45 (= 1), 46-50 (= 2), 51-55 (= 3), 56-60 (= 4), 61-65 (= 5), 66-70 (= 6), 
71-75 (= 7), 76-80 (= 8), 81-85 (= 9), and 86 or above (= 10). Tumor size was collapsed 
into three groups: size less than 15mm (= 0), between 15mm and 30mm (= 1), and larger 
than 30mm (= 2). ‘Censor’ is coded ‘0’ if the patient died before the end of the study and 
‘1’ if the patient survived at the end of the study. It is worth mentioning that all recorded 
deaths in this study were due to prostate cancer. The conceptual diagram for the prostate 
cancer modeling is shown in Figure 4.1. 
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Figure 4.1 Conceptual Diagram for the Prostate Cancer Modeling 
4.2 Parametric Regression Modeling for White in Stage I 
Case 0: No Treatment (Watchful Waiting) 
A scatter plot of the survival time a function of age for all prostate cancer patients in the 
interval 36 to 98 years is given by Figure 4.2. 
 
Figure 4.2 Mean Survival Time for Whites undergoing Surgery in Stage I 
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Figure 4.2 shows that the linear function is not the same across all ages, thus, we 
partitioned the survival time into every five years of age. A linear function was fitted to 
the observed data and the actual mean  ̅ and the expected value E(x) were calculated to 
evaluate the quality of the selected linear model that best describe the survival time as a 
function of age and the results are shown in Table 4.1. 
Table 4.1 Estimated Mean Survival Time for Whites undergoing Surgery by Age Group in Stage I 
Stage I: Surgery for Whites 
Age Group  ̅ Linear Equation E(Y) 
Age 1 (36-40) 11.42                  11.542 
Age 2 (41-45) 11.27               11.273 
Age 3 (46-50) 10.12                   10.121 
Age 4 (51-55) 9.66               9.664 
Age 5 (56-60) 10.34                  10.336 
Age 6 (61-65) 11.18                  11.186 
Age 7 (66-70) 9.79                   9.791 
Age 8 (71-75) 9.04                   9.0345 
Age 9 (76-80) 6.97                   6.9758 
Age 10 (81-85) 5.31                   5.3073 
Age 11 (86+) 2.95                   2.9494 
 
Table 4.1 revealed that the expected value E(x) is approximately the same as the actual 
mean  ̅. Therefore, using five years of age partition might improve the strength of the 
survival model. Using the same criteria above, five years of age partition could be 
justified under watchful waiting, radiation therapy, surgery, and combination of radiation 
and surgery at four stages of prostate cancer. 
A scatter plot of the survival time a function of tumor size for all prostate cancer 
patients is given by Figure 4.3. It shows that the linear function is not the same across all 
tumor size, thus, we partitioned the survival time into three groups:  size less than 15mm 
(= 0), between 15mm and 30mm (= 1), and larger than 30mm (= 2). A linear function 
was fitted to the observed data and the actual mean  ̅ and the expected value E(x) were 
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calculated to evaluate the quality of the selected linear model that best describe the 
survival time as a function of tumor size and the results are shown in Table 4.2. 
 
Figure 4.3 Mean Survival Time as a Function of Tumor Size undergoing Surgery in Stage I 
 
Table 4.2 Estimated Mean Survival Time for Whites undergoing Surgery by Tumor Size in Stage I 
Stage I: Surgery for Whites 
Tumor Size Group  ̅ Linear Equation E(Y) 
< 15mm 9.79                  9.7926 
15mm – 30mm 10.20                  10.1985 
Above 30mm 9.49                   9.4878 
 
Table 4.2 revealed that the expected value E(x) is approximately the same as the actual 
mean  ̅. Therefore, the partition of the tumor size might improve the strength of the 
survival model. Using the same criteria above, the tumor size partition could be justified 
under watchful waiting, radiation therapy, surgery, and combination of radiation and 
surgery at each stage of prostate cancer. 
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Using this analytical structure, our goal is to evaluate the effectiveness of the 
treatment methods: ‘No Treatment ’, ‘Surgery ’, ‘Radiation therapy and ‘Surgery & 
Radiation’ by race and stage with the predictors (age at diagnosis, tumor size, and 
interaction between age at diagnosis and tumor size). Using age (36 - 40) and tumor size 
(< 15mm) as reference.   
Let                                                   
                                                               
                                                                
                               
       ̂   ̂     ̂     ̂     ̂     ̂     ̂     ̂     ̂     ̂   
  ̂       ̂       ̂       ̂         ̂         ̂       
  ̂         ̂         ̂         ̂         ̂       
  ̂         ̂          ̂         ̂         ̂       
  ̂         ̂         ̂         ̂         ̂       
  ̂         ̂            
Suppose T, followed a gamma distribution, denote a continuous non-negative random 
variable representing survival time.  The analytical structure of the failure model under 
gamma distribution is given by: 
            ,  
where   and   are the shape and scale parameters, respectively. 
Adding covariates into shape parameter, we have 
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        are the regression coefficients of interest, and  follows log-gamma 
distribution, or as: 
  
   
 
 
The probability density function of W is given by: 
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The cumulative distribution function of W is: 
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Thus, the survival function is 
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The likelihood function for right censored data is denoted by 
  ∏       
 
   
           
        
where   indicates whether duration time t is uncensored (     or censored (      
To estimate the regression coefficient   , one may take a partial derivate with 
respect to a specific parameter for the log-likelihood function and set the equation equals 
to zero. The numerical analysis could be performed to maximize the log-likelihood 
function to estimate the parameters. The routines to do so are available in SAS procedure 
LIFEREG in SAS statistical package (SAS Institute, 1985). The common numerically 
method is using the Newton-Raphson algorithm. 
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The estimated parametric regression model for White in stage I under watchful waiting is 
given by 
                                                          
                                                           
                                                            
                                                            
                             (4.1). 
To validate the survival model, residual analysis was performed on the equation (4.1). By 
taking the exponential of the regression model and using the dataset, we could estimate 
the survival time. To calculate the residuals, we subtract the estimated survival time from 
the actual survival time. The results of the residuals produced a residual mean, standard 
error, and variances are 0.4223, 1.2321, and 1.5181, respectively. This indicates that the 
equation (4.1) is overestimated and can be improve by subtracting the correction factor 
(0.4223) to the model. Thus, the corrected parametric regression model is given by: 
                                                          
                                                           
                                                            
                                                            
                                    (4.2). 
Based on the regression coefficients    and the corrected regression model, we could 
estimate the survival time by taking the exponential of the equation (4.2) and using the 
dataset. Different classical distributions were fitted to the estimated survival times. The 
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best fitted probability distribution function that characterized the estimated survival times 
was the gamma distribution with approximate maximum likelihood estimates  ̂  
       and  ̂        . The corresponding E(x), median, and 95% confident limit are 
9.21, 8.28, and (2.07, 21.57) respectively. Figure 4.4 showed the estimated survival 
function for White under watchful waiting based on the survival model. 
 
Figure 4.4 Estimated Survival Function for Whites under Watchful Waiting in Stage I 
Notice that the time t=0 year: patients were diagnosed with prostate cancer and under 
watchful waiting. Thus, a physician could be able to answer questions from a patient 
under watchful waiting; the probability of the patient will survive in 10 years is 
approximately 37%. Also, the probability of a given patient that will survive the expected 
survival time of 9 years is approximately 44%. 
Case I: Radiation therapy 
The estimated parametric regression model for White in stage I receiving 
radiation therapy is given by: 
                                                          
                                                         
20151050
1.0
0.8
0.6
0.4
0.2
0.0
Time in Year
S
u
rv
iv
a
l 
P
ro
b
a
b
ili
ty
Estimated Survival Function for Whites under Watchful Waiting in Stage I
75 
 
                                                            
                                                            
                                        (4.3). 
Residual analysis was performed on the equation (4.3) and produced a residual mean, 
standard error, and variances are 0.5125, 1.4125, and 1.3053, respectively. This indicates 
that the equation (4.3) is overestimated and can be improve by subtracting the correction 
factor (0.5125) to the model. Thus, the corrected parametric regression model is given by: 
                                                          
                                                         
                                                            
                                                            
                                              (4.4). 
Based on the regression coefficients    and the corrected regression model, we could 
estimate the survival time by taking the exponential of the equation (4.4) and using the 
dataset. Different classical distributions were fitted to the estimated survival times. The 
best fitted probability distribution function that characterized the estimated survival times 
was the gamma distribution with approximate maximum likelihood estimates  ̂         
and  ̂        . The corresponding E(x), median, and 95% confident limit are 13.00, 
12.23, and (4.57, 25.75) respectively. Figure 4.5 showed the estimated survival function 
for White receiving radiation therapy based on the survival model. 
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Figure 4.5 Estimated Survival Function for Whites receiving Radiation Therapy in Stage I 
Notice that the time t=0 year: patients were diagnosed with prostate cancer and proceed 
to radiation therapy. Thus, a physician could be able to answer questions from a patient 
after radiation therapy; the probability of the patient will survive in 10 years is 
approximately 67%. Also, the probability of a given patient that will survive the expected 
survival time of 13 years is approximately 44%. 
Case II: Surgery 
The parametric regression model for White in stage I undergoing surgery is given 
by: 
                                                          
                                                       
                                                          
                                                             
                                                            
                                                   (4.5). 
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Residual analysis was performed on the equation (4.5) and produced a residual mean, 
standard error, and variances are 0.0821, 1.5517, and 2.4078, respectively. This indicates 
that the equation (4.5) is overestimated and can be improve by subtracting the correction 
factor (0.0821) to the model. Thus, the corrected parametric regression model is given by, 
                                                          
                                                       
                                                          
                                                             
                                                            
                                                        (4.6). 
Based on the regression coefficients    and the corrected regression model, we could 
estimate the survival time by taking the exponential of the equation (4.6) and the dataset. 
Different classical distributions were fitted to the estimated survival times. The best fitted 
probability distribution function that characterized the estimated survival times was the 
gamma distribution. The approximate maximum likelihood estimates 
 ̂         and  ̂        . The corresponding E(x), median, and 95% confident limit 
are 14.36, 13.27, and (4.18, 30.71) respectively. A graphical display of the estimated 
survival function for White undergoing surgery based on the survival model is showed by 
Figure 4.6. 
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Figure 4.6 Estimated Survival Function for Whites undergoing Surgery in Stage I 
Notice that the time t=0 year: patients were diagnosed with prostate cancer and proceed 
with surgery. Thus, a physician could be able to answer questions from a patient after 
surgery; the probability of the patient will survive in 10 years is approximately 70%. 
Also, the probability of a given patient that will survive the expected survival time of 14 
years is approximately 46%. 
Case III: Combination of Radiation and Surgery 
The parametric regression model for White in stage I receiving both radiation therapy and 
surgery with the corrected factor is given by: 
                                                            
                                                          
                                                          
                                                             
                                     (4.7). 
The results of residual analysis produced a residual mean, standard error, and variances 
are 0.04125, 1.1087, and 1.2292, respectively. Based on the regression coefficients    and 
the corrected regression model, we could estimate the survival time by taking the 
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exponential of the equation (4.7) and using the dataset. Different classical distributions 
were fitted to the estimated survival times. The best fitted probability distribution 
function that characterized the estimated survival times was the gamma distribution. The 
approximate maximum likelihood estimates  ̂         and  ̂        . The 
corresponding E(x), median, and 95% confident limit are 13.81, 12.95, and (4.66, 27.84) 
respectively. A graphical display of the estimated survival function for White receiving 
both radiation and surgery based on the survival model is showed by Figure 4.7. 
 
Figure 4.7 Estimated Survival Function for Whites receiving both Radiation and Surgery in Stage I 
Notice that the time t=0 year: patients were diagnosed with prostate cancer and proceed 
with both surgery and radiation. Thus, a physician could be able to answer questions from 
a patient after both surgery and radiation therapy; the probability of the patient will 
survive in 10 years is approximately 71%. Also, the probability of a given patient that 
will survive the expected survival time of 14 years is approximately 43%. 
In view of these cases, a graphical display of the estimated survival functions for White 
men undergoing different treatment of prostate cancer is given by Figure 4.8.  
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Figure 4.8 Estimated Survival Function for Whites by Treatment in Stage I 
It appears patients undergoing surgery, radiation therapy, or both radiation and surgery 
have better survivorship than the patients under watchful waiting. However, it could not 
distinguish the differences in survivorship among the three types of treatments. We 
proceed to evaluate survival probability in different treatment by discretizing the time 
points and the results are shown in Table 4.3.  
In determining the treatment response for each year, we performed a pairwise 
comparison between two treatments at each time point is defined as the survival 
probability residuals. 
Let   ̂     represent the survival probability residual between no treatment and radiation 
therapy. That is: 
  ̂      ̂        ̂                      
  ̂      represents the survival probability residual between no treatment and surgery. 
That is: 
  ̂       ̂        ̂                       
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  ̂      represents the survival probability residual between no treatment and 
combination of radiation and surgery. That is: 
  ̂       ̂        ̂                       
Table 4.3 Survival Probability for Whites in Stage I by Treatment 
  Survival Probability 
Time in Year NT Rad Surg Comb 
1 0.9969 1.0000 0.9999 1.0000 
2 0.9773 0.9994 0.9983 0.9993 
3 0.9343 0.9959 0.9922 0.9959 
4 0.8699 0.9855 0.9785 0.9864 
5 0.7901 0.9643 0.9552 0.9674 
6 0.7019 0.9297 0.9217 0.9370 
7 0.6116 0.8813 0.8785 0.8946 
8 0.5239 0.8205 0.8270 0.8412 
9 0.4423 0.7501 0.7692 0.7790 
10 0.3685 0.6738 0.7073 0.7107 
11 0.3036 0.5952 0.6434 0.6391 
12 0.2476 0.5176 0.5793 0.5669 
13 0.2002 0.4435 0.5167 0.4966 
14 0.1605 0.3748 0.4569 0.4299 
15 0.1278 0.3128 0.4008 0.3680 
16 0.1011 0.2581 0.3489 0.3119 
17 0.0795 0.2106 0.3016 0.2618 
18 0.0622 0.1702 0.2591 0.2179 
19 0.0484 0.1362 0.2213 0.1798 
20 0.0375 0.1082 0.1879 0.1473 
 
  ̂       represents the survival probability residual between radiation therapy and 
surgery. That is: 
  ̂        ̂         ̂                       
  ̂       represents the survival probability residual between radiation therapy and 
combination of radiation and surgery. That is: 
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  ̂        ̂         ̂                       
  ̂        represents the survival probability residual between surgery and combination 
of radiation and surgery. That is: 
  ̂         ̂          ̂                       
The estimated mean probability residual between watchful waiting and radiation therapy 
is approximately -0.177, between watchful waiting and surgery is approximately -0.218, 
and between watchful waiting and combination of radiation and surgery is approximately 
-0.207, between radiation therapy and surgery is approximately -0.041, between radiation 
therapy and combination of radiation and surgery is approximately -0.03, and between 
surgery and combination of radiation and surgery is approximately 0.011. A series of 
hypothesis tests was performed to compare the significant differences between two 
treatments. The results were found significant between watchful waiting and radiation 
therapy (p < 0.0001), between watchful waiting and surgery (p < 0.0001), between 
watchful waiting and combination of radiation and surgery (p < 0.0001), between 
radiation therapy and surgery (p < 0.0001), and between radiation therapy and 
combination of radiation and surgery (p < 0.0001), However, there is no statistical 
difference between surgery and combination of radiation and surgery with a p-value of 
0.075. The nonparametric test also verified our decision and the results are consistent.  
4.3 Parametric Regression Modeling for White in Stage II 
Case 0: No Treatment (Watchful Waiting) 
The estimated parametric regression model for White in stage II under watchful waiting 
with the corrected factor is given by: 
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                                                        (4.8). 
The results of residual analysis produced a residual mean, standard error, and variances 
are 0.7121, 1.8702, and 3.4976, respectively. Based on the regression coefficients    and 
the corrected regression model, we could estimate the survival time by taking the 
exponential of the equation (4.8) and using the dataset. Different classical distributions 
were fitted to the estimated survival times. The best fitted probability distribution 
function that characterized the estimated survival times was the gamma distribution with 
approximate maximum likelihood estimates  ̂         and  ̂        . The 
corresponding E(x), median, and 95% confident limit are 9.62, 8.75, and (2.39, 21.80), 
respectively. Figure 4.9 showed the estimated survival function for White under watchful 
waiting based on the survival model. 
 
Figure 4.9 Estimated Survival Function for Whites under Watchful Waiting in Stage II 
Notice that the time t=0 year: patients were diagnosed with prostate cancer and under 
watchful waiting. Thus, a physician could be able to answer questions from a patient 
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under watchful waiting; the probability of the patient will survive in 10 years is 
approximately 40%. Also, the probability of a given patient that will survive the expected 
survival time of 9 years is approximately 48%. 
Case I: Radiation therapy 
The estimated parametric regression model for White in stage II receiving radiation 
therapy with the corrected factor is given by: 
                                                          
                                                              
                                                            
                                               (4.9). 
The results of residual analysis produced a residual mean, standard error, and variances 
are 0.4289, 2.0152, and 4.0610, respectively. Based on the regression coefficients    and 
the corrected regression model, we could estimate the survival time by taking the 
exponential of the equation (4.9) and using the dataset. Different classical distributions 
were fitted to the estimated survival times. The best fitted probability distribution 
function that characterized the estimated survival times was the gamma distribution with 
approximate maximum likelihood estimates  ̂         and  ̂        . The 
corresponding E(x), median, and 95% confident limit are 13.15, 12.23, and (4.09, 27.40) 
respectively. Figure 4.10 showed the estimated survival function for White receiving 
radiation therapy based on the survival model. 
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Figure 4.10 Estimated Survival Function for Whites receiving Rad in Stage II 
Notice that the time t=0 year: patients were diagnosed with prostate cancer and proceed 
with radiation therapy. Thus, a physician could be able to answer questions from a patient 
after radiation therapy; the probability of the patient will survive in 10 years is 
approximately 66%. Also, the probability of a given patient that will survive the expected 
survival time of 13 years is approximately 45%. 
Case II: Surgery 
The corrected parametric regression model for White in stage II undergoing surgery is 
given by: 
                                                          
                                                        
                                                             
                                                            
                                                            
                          (4.10). 
The results of residual analysis produced a residual mean, standard error, and variances 
are 0.7128, 0.9316, and 0.8679, respectively. Based on the regression coefficients    and 
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the corrected regression model, we could estimate the survival time by taking the 
exponential of the equation (4.10) and using the dataset. Different classical distributions 
were fitted to the estimated survival times. The best fitted probability distribution 
function that characterized the estimated survival times was the gamma distribution with 
the approximate maximum likelihood estimates  ̂         and  ̂        . The 
corresponding E(x), median, and 95% confident limit are 14.42, 13.56, and (5.01, 28.71) 
respectively. A graphical display of the estimated survival function for White undergoing 
surgery based on the survival model is showed by Figure 4.11. 
 
Figure 4.11 Estimated Survival Function for Whites undergoing Surgery in Stage II 
Notice that the time t=0 year: patients were diagnosed with prostate cancer and proceed 
with surgery. Thus, a physician could be able to answer questions from a patient after 
surgery; the probability of the patient will survive in 10 years is approximately 75%. 
Also, the probability of a given patient that will survive the expected survival time of 14 
years is approximately 47%. 
Case III: Combination of Radiation and Surgery 
The parametric regression model for White in stage II receiving both radiation therapy 
and surgery with the corrected factor is given by: 
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                                              (4.11). 
The results of residual analysis produced a residual mean, standard error, and variances 
are 0.0284, 1.1268, and 1.2697, respectively. Based on the regression coefficients    and 
the corrected regression model, we could estimate the survival time by taking the 
exponential of the equation (4.11) and using the dataset. Different classical distributions 
were fitted to the estimated survival times. The best fitted probability distribution 
function that characterized the estimated survival times was the gamma distribution. The 
approximate maximum likelihood estimates  ̂         and  ̂        . The 
corresponding E(x), median, and 95% confident limit are 13.55, 12.65, and (4.39, 27.78) 
respectively. A graphical display of the estimated survival function for White receiving 
both radiation and surgery based on the survival model is showed by Figure 4.12. 
 
Figure 4.12 Estimated Survival Function for Whites receiving both Rad & Surg in Stage II 
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Notice that the time t=0 year: patients were diagnosed with prostate cancer and proceed 
with both surgery and radiation. Thus, a physician could be able to answer questions from 
a patient after both surgery and radiation; the probability of the patient will survive in 10 
years is approximately 69%. Also, the probability of a given patient that will survive the 
expected survival time of 13 years is approximately 48%. 
Combined these cases, a graphical display of the estimated survival functions for 
White men undergoing different treatment of prostate cancer is given by Figure 4.13.  
 
Figure 4.13 Stage II: Estimated Survival Function for Whites by Treatments 
It appears patients undergoing surgery, radiation therapy, or both radiation and surgery 
have better survivorship than the patients under watchful waiting. Also, patients 
undergoing surgery have higher survivorship compared to the patients receiving radiation 
therapy or combination of radiation and surgery. However, it could not distinguish the 
differences in survivorship between radiation therapy and combination of radiation and 
surgery. We proceed to evaluate survival probability in different treatment by discretizing 
the time points and the results are shown in Table 4.4.  
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Table 4.4 Survival Probability for Whites in Stage II by Treatment 
  Survival Probability 
Time in Year NT Rad Surg Comb 
1 0.9984 0.9999 1.0000 1.0000 
2 0.9852 0.9984 0.9996 0.9990 
3 0.9520 0.9921 0.9972 0.9943 
4 0.8973 0.9769 0.9901 0.9823 
5 0.8251 0.9501 0.9753 0.9599 
6 0.7414 0.9107 0.9502 0.9255 
7 0.6525 0.8595 0.9140 0.8792 
8 0.5636 0.7987 0.8669 0.8226 
9 0.4790 0.7310 0.8104 0.7580 
10 0.4012 0.6595 0.7467 0.6884 
11 0.3317 0.5870 0.6783 0.6167 
12 0.2712 0.5160 0.6080 0.5453 
13 0.2195 0.4483 0.5381 0.4764 
14 0.1760 0.3854 0.4706 0.4116 
15 0.1400 0.3281 0.4070 0.3519 
16 0.1105 0.2767 0.3483 0.2980 
17 0.0867 0.2315 0.2952 0.2502 
18 0.0676 0.1921 0.2480 0.2083 
19 0.0524 0.1583 0.2066 0.1721 
20 0.0404 0.1296 0.1707 0.1412 
 
In determining the treatment response for each year, we performed a pairwise comparison 
between two treatments at each time point is defined as the survival probability residuals. 
The estimated mean probability residual between watchful waiting and radiation therapy 
is approximately -0.1569, between watchful waiting and surgery is approximately -
0.2115, and between watchful waiting and combination of radiation and surgery is 
approximately -0.1744, between radiation therapy and surgery is approximately -0.0546, 
between radiation therapy and combination of radiation and surgery is approximately -
0.0175, and between surgery and combination of radiation and surgery is approximately 
0.0370. A series of hypothesis tests was performed to compare the significant differences 
between two treatments. The results were found significant between watchful waiting and 
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radiation therapy (p < 0.0001), between watchful waiting and surgery (p < 0.0001), 
between watchful waiting and combination of radiation and surgery (p < 0.0001), 
between radiation therapy and surgery (p < 0.0001), between radiation therapy and 
combination of radiation and surgery (p < 0.0001), and between surgery and combination 
of radiation and surgery (p < 0.0001). The nonparametric test also verified our decision 
and the results are consistent.  
4.4 Parametric Regression Modeling for White in Stage III 
Case 0: No Treatment (Watchful Waiting) 
The estimated parametric regression model for White in stage III under watchful 
waiting with the corrected factor is given by: 
                                                          
                                                              
                                                         (4.12). 
The results of residual analysis produced a residual mean, standard error, and variances 
are 0.9871, 2.5471, and 6.4877, respectively. Based on the regression coefficients    and 
the corrected regression model, we could estimate the survival time by taking the 
exponential of the equation (4.12) and using the dataset. Different classical distributions 
were fitted to the estimated survival times. The best fitted probability distribution 
function that characterized the estimated survival times was the gamma distribution with 
approximate maximum likelihood estimates  ̂         and  ̂        . The 
corresponding E(x), median, and 95% confident limit are 8.96, 7.73, and (1.37, 23.52) 
respectively. Figure 4.14 showed the estimated survival function for White under 
watchful waiting based on the survival model. 
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Figure 4.14 Estimated Survival Function for Whites under Watchful Waiting in Stage III 
Notice that the time t=0 year: patients were diagnosed with prostate cancer and under 
watchful waiting. Thus, a physician could be able to answer questions from a patient 
under watchful waiting; the probability of the patient will survive in 10 years is 
approximately 35%. Also, the probability of a given patient that will survive the expected 
survival time of 9 years is approximately 41%. 
Case I: Radiation therapy 
The estimated parametric regression model for White in stage III receiving 
radiation therapy with the corrected factor is given by: 
                                                          
                                                           
                                                            
                                                            
                (4.13). 
The results of residual analysis produced a residual mean, standard error, and variances 
are 0.3285, 1.8871, and 3.5611, respectively. Based on the regression coefficients    and 
the corrected regression model, we could estimate the survival time by taking the 
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exponential of the equation (4.13) and using the dataset. Different classical distributions 
were fitted to the estimated survival times. The best fitted probability distribution 
function that characterized the estimated survival times was the gamma distribution with 
approximate maximum likelihood estimates  ̂         and  ̂        . The 
corresponding E(x), median, and 95% confident limit are 12.49, 11.38, and (3.17, 28.10) 
respectively. Figure 4.15 showed the estimated survival function for White receiving 
radiation therapy based on the survival model. 
 
Figure 4.15 Estimated Survival Function for Whites receiving Rad in Stage III 
Notice that the time t=0 year: patients were diagnosed with prostate cancer and proceed 
with radiation. Thus, a physician could be able to answer questions from a patient after 
radiation; the probability of the patient will survive in 10 years is approximately 59%. 
Also, the probability of a given patient that will survive the expected survival time of 12 
years is approximately 46%. 
Case II: Surgery 
The corrected parametric regression model for White in stage III undergoing surgery is 
given by: 
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                          (4.14). 
The results of residual analysis produced a residual mean, standard error, and variances 
are 0.0039, 1.0511, and 1.1048, respectively. Based on the regression coefficients    and 
the corrected regression model, we could estimate the survival time by taking the 
exponential of the equation (4.14) and using the dataset. Different classical distributions 
were fitted to the estimated survival times. The best fitted probability distribution 
function that characterized the estimated survival times was the gamma distribution with 
the approximate maximum likelihood estimates  ̂         and  ̂        . The 
corresponding E(x), median, and 95% confident limit are 13.53, 12.86, and (5.31, 25.52) 
respectively. A graphical display of the estimated survival function for White undergoing 
surgery based on the survival model is showed by Figure 4.16. 
 
Figure 4.16 Estimated Survival Function for Whites undergoing Surgery in Stage III 
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Notice that the time t=0 year: patients were diagnosed with prostate cancer and proceed 
with surgery. Thus, a physician could be able to answer questions from a patient after 
surgery; the probability of the patient will survive in 10 years is approximately 73%. 
Also, the probability of a given patient that will survive the expected survival time of 13 
years is approximately 49%. 
Case III: Combination of Radiation and Surgery 
The parametric regression model for White in stage III receiving both radiation 
therapy and surgery with the corrected factor is given by: 
                                                          
                                                           
                                                            
                                    (4.15). 
The results of residual analysis produced a residual mean, standard error, and variances 
are 1.0125, 2.0187, and 4.0751, respectively. Based on the regression coefficients    and 
the corrected regression model, we could estimate the survival time by taking the 
exponential of the equation (4.15) and using the dataset. Different classical distributions 
were fitted to the estimated survival times. The best fitted probability distribution 
function that characterized the estimated survival times was the gamma distribution. The 
approximate maximum likelihood estimates  ̂         and  ̂        . The 
corresponding E(x), median, and 95% confident limit are 15.30, 14.46, and (5.63, 29.74) 
respectively. A graphical display of the estimated survival function for White receiving 
both radiation and surgery based on the survival model is showed by Figure 4.17. 
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Figure 4.17 Estimated Survival Function for Whites receiving both Rad & Surg in Stage III 
Notice that the time t=0 year: patients were diagnosed with prostate cancer and proceed 
with both surgery and radiation. Thus, a physician could be able to answer questions from 
a patient after both surgery and radiation; the probability of the patient will survive in 10 
years is approximately 80%. Also, the probability of a given patient that will survive the 
expected survival time of 14 years is approximately 53%. 
Combined these cases, a graphical display of the estimated survival functions for 
White men undergoing different treatment of prostate cancer is given by Figure 4.18.  
 
Figure 4.18 Stage III: Estimated Survival Function for Whites by Treatment 
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The graphs revealed that the most effective treatments for white men in stage III are 
combination of radiation and surgery, followed by surgery, next radiation therapy, finally 
under watchful waiting. We proceed to evaluate survival probability in different 
treatment by discretizing the time points and the results are shown in Table 4.5.  
In determining the treatment response for each year, we performed a pairwise 
comparison between two treatments at each time point is defined as the survival 
probability residuals. The estimated mean probability residual between watchful waiting 
and radiation therapy is approximately -0.1592, between watchful waiting and surgery is 
approximately -0.2215, and between watchful waiting and combination of radiation and 
surgery is approximately -0.2845, between radiation therapy and surgery is 
approximately -0.0622, between radiation therapy and combination of radiation and 
surgery is approximately -0.1253, and between surgery and combination of radiation and 
surgery is approximately -0.0631. A series of hypothesis tests was performed to compare 
the significant differences between two treatments. The results were found significant 
between watchful waiting and radiation therapy (p < 0.0001), between watchful waiting 
and surgery (p < 0.0001), between watchful waiting and combination of radiation and 
surgery (p < 0.0001), between radiation therapy and surgery (p < 0.0001), between 
radiation therapy and combination of radiation and surgery (p < 0.0001), and between 
surgery and combination of radiation and surgery (p < 0.0001). The nonparametric test 
also verified our decision and the results are consistent.  
  
97 
 
Table 4.5 Survival Probability for Whites in Stage III by Treatment 
  Survival Probability 
Time in Year NT Rad Surg Comb 
1 0.9873 0.9994 1.0000 1.0000 
2 0.9458 0.9940 0.9999 0.9998 
3 0.8822 0.9787 0.9986 0.9987 
4 0.8049 0.9508 0.9936 0.9946 
5 0.7214 0.9101 0.9810 0.9849 
6 0.6371 0.8581 0.9572 0.9673 
7 0.5557 0.7975 0.9197 0.9399 
8 0.4798 0.7312 0.8680 0.9020 
9 0.4106 0.6621 0.8038 0.8542 
10 0.3488 0.5927 0.7300 0.7978 
11 0.2943 0.5251 0.6504 0.7349 
12 0.2469 0.4608 0.5689 0.6679 
13 0.2060 0.4009 0.4890 0.5992 
14 0.1712 0.3461 0.4135 0.5310 
15 0.1416 0.2966 0.3443 0.4650 
16 0.1168 0.2525 0.2826 0.4029 
17 0.0959 0.2137 0.2289 0.3454 
18 0.0786 0.1799 0.1831 0.2933 
19 0.0642 0.1506 0.1449 0.2468 
20 0.0523 0.1255 0.1134 0.2060 
 
4.5 Parametric Regression Modeling for White in Stage IV 
Case 0: No Treatment (Watchful Waiting) 
The estimated parametric regression model for White in stage IV under watchful 
waiting with the corrected factor is given by: 
                                                          
                                                        
                                                            
                                                            
                           (4.16). 
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The results of residual analysis produced a residual mean, standard error, and variances 
are 1.5826, 2.3698, and 5.6160, respectively. Based on the regression coefficients    and 
the corrected regression model, we could estimate the survival time by taking the 
exponential of the equation (4.16) and using the dataset. Different classical distributions 
were fitted to the estimated survival times. The best fitted probability distribution 
function that characterized the estimated survival times was the gamma distribution with 
approximate maximum likelihood estimates  ̂         and  ̂        . The 
corresponding E(x), median, and 95% confident limit are 6.30, 5.05, and (0.52, 19.10) 
respectively. Figure 4.19 showed the estimated survival function for White under 
watchful waiting based on the survival model. 
 
Figure 4.19 Estimated Survival Function for Whites under Watchful Waiting in Stage IV 
Notice that the time t=0 year: patients were diagnosed with prostate cancer and under 
watchful waiting. Thus, a physician could be able to answer questions from a patient 
under watchful waiting; the probability of the patient will survive in 10 years is 
approximately 19%. Also, the probability of a given patient that will survive the expected 
survival time of 6 years is approximately 42%. 
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Case I: Radiation therapy 
The estimated parametric regression model for White in stage IV receiving 
radiation therapy with the corrected factor is given by: 
                                                          
                                                           
                                                            
                 (4.17). 
The results of residual analysis produced a residual mean, standard error, and variances 
are 1.0528, 1.8523, and 3.4310, respectively. Based on the regression coefficients    and 
the corrected regression model, we could estimate the survival time by taking the 
exponential of the equation (4.17) and using the dataset. Different classical distributions 
were fitted to the estimated survival times. The best fitted probability distribution 
function that characterized the estimated survival times was the gamma distribution with 
approximate maximum likelihood estimates  ̂         and  ̂        . The 
corresponding E(x), median, and 95% confident limit are 10.22, 8.95, and (1.80, 25.80) 
respectively. Figure 4.20 showed the estimated survival function for White receiving 
radiation therapy based on the survival model. 
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Figure 4.20 Estimated Survival Function for Whites receiving Rad in Stage IV 
Notice that the time t=0 year: patients were diagnosed with prostate cancer and proceed 
with radiation therapy. Thus, a physician could be able to answer questions from a patient 
after radiation therapy; the probability of the patient will survive in 10 years is 
approximately 43%. Also, the probability of a given patient that will survive the expected 
survival time of 10 years is approximately 43%. 
Case II: Surgery 
The corrected parametric regression model for White in stage IV undergoing 
surgery is given by: 
                                                          
                                                           
                                                            
                                               (4.18). 
The results of residual analysis produced a residual mean, standard error, and variances 
are 0.0715, 1.3395, and 1.7943, respectively. Based on the regression coefficients    and 
the corrected regression model, we could estimate the survival time by taking the 
exponential of the equation (4.18) and using the dataset. Different classical distributions 
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were fitted to the estimated survival times. The best fitted probability distribution 
function that characterized the estimated survival times was the gamma distribution with 
the approximate maximum likelihood estimates  ̂         and  ̂        . The 
corresponding E(x), median, and 95% confident limit are 10.64, 9.72, and (2.76, 23.74) 
respectively. A graphical display of the estimated survival function for White undergoing 
surgery based on the survival model is showed by Figure 4.21. 
 
Figure 4.21 Estimated Survival Function for Whites undergoing Surg in Stage IV 
Notice that the time t=0 year: patients were diagnosed with prostate cancer and proceed 
with surgery. Thus, a physician could be able to answer questions from a patient after 
surgery; the probability of the patient will survive in 10 years is approximately 48%. 
Also, the probability of a given patient that will survive the expected survival time of 11 
years is approximately 41%. 
Case III: Combination of Radiation and Surgery 
The parametric regression model for White in stage IV receiving both radiation 
therapy and surgery with the corrected factor is given by: 
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                                     (4.19). 
The results of residual analysis produced a residual mean, standard error, and variances 
are 0.0921, 2.3918, and 5.7207, respectively. Based on the regression coefficients    and 
the corrected regression model, we could estimate the survival time by taking the 
exponential of the equation (4.19) and using the dataset. Different classical distributions 
were fitted to the estimated survival times. The best fitted probability distribution 
function that characterized the estimated survival times was the gamma distribution. The 
approximate maximum likelihood estimates  ̂         and  ̂        . The 
corresponding E(x), median, and 95% confident limit are 11.51, 10.47, and (2.86, 26.07) 
respectively. A graphical display of the estimated survival function for White receiving 
both radiation and surgery based on the survival model is showed by Figure 4.22. 
 
Figure 4.22 Estimated Survival Function for Whites receiving both Rad & Surg in Stage IV 
Notice that the time t=0 year: patients were diagnosed with prostate cancer and proceed 
with both surgery and radiation. Thus, a physician could be able to answer questions from 
a patient after both surgery and radiation; the probability of the patient will survive in 10 
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years is approximately 53%. Also, the probability of a given patient that will survive the 
expected survival time of 11 years is approximately 46%. 
Combined these cases, a graphical display of the estimated survival functions for 
White men undergoing different treatment of prostate cancer is given by Figure 4.23.  
 
Figure 4.23 Stage IV: Estimated Survival Function for Whites by Treatment 
It appears patients undergoing surgery, radiation therapy, or both radiation and surgery 
have better survivorship than the patients under watchful waiting. Also, patients 
undergoing combination of radiation and surgery have higher survivorship compared to 
the patients receiving radiation therapy or undergoing surgery. However, it could not 
distinguish the differences in survivorship between radiation therapy and surgery. We 
proceed to evaluate survival probability in different treatment by discretizing the time 
points and the results are shown in Table 4.6.  
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Table 4.6 Survival Probability for Whites in Stage IV by Treatment 
  Survival Probability 
Time in Year NT Rad Surg Comb 
1 0.9338 0.9938 0.9991 0.9991 
2 0.8265 0.9681 0.9909 0.9916 
3 0.7122 0.9229 0.9680 0.9713 
4 0.6034 0.8626 0.9272 0.9359 
5 0.5051 0.7925 0.8697 0.8861 
6 0.4189 0.7174 0.7992 0.8246 
7 0.3450 0.6412 0.7205 0.7551 
8 0.2825 0.5669 0.6384 0.6812 
9 0.2302 0.4964 0.5568 0.6064 
10 0.1868 0.4310 0.4788 0.5332 
11 0.1512 0.3716 0.4065 0.4637 
12 0.1219 0.3183 0.3413 0.3994 
13 0.0981 0.2710 0.2836 0.3408 
14 0.0788 0.2296 0.2335 0.2885 
15 0.0631 0.1936 0.1907 0.2425 
16 0.0505 0.1626 0.1545 0.2024 
17 0.0403 0.1360 0.1244 0.1679 
18 0.0321 0.1134 0.0994 0.1385 
19 0.0256 0.0942 0.0791 0.1137 
20 0.0203 0.0780 0.0625 0.0929 
 
In determining the treatment response for each year, we performed a pairwise comparison 
between two treatments at each time point is defined as the survival probability residuals. 
The estimated mean probability residual between watchful waiting and radiation therapy 
is approximately -0.1817, between watchful waiting and surgery is approximately -
0.2099, and between watchful waiting and combination of radiation and surgery is 
approximately -0.2454, between radiation therapy and surgery is approximately -0.0281, 
between radiation therapy and combination of radiation and surgery is approximately -
0.0637, and between surgery and combination of radiation and surgery is approximately -
0.0355. A series of hypothesis tests was performed to compare the significant differences 
between two treatments. The results were found significant between watchful waiting and 
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radiation therapy (p < 0.0001), between watchful waiting and surgery (p < 0.0001), 
between watchful waiting and combination of radiation and surgery (p < 0.0001), 
between radiation therapy and surgery (p = 0.002), between radiation therapy and 
combination of radiation and surgery (p < 0.0001), and between surgery and combination 
of radiation and surgery (p < 0.0001). The nonparametric test also verified our decision 
and the results are consistent.  
4.6 Conclusion 
In this study, parametric survival modeling was performed to evaluate the most 
effective treatment for Whites undergoing different treatment at a particular stage of 
prostate cancer considering the risk factors: age at diagnosis, size of tumor, and the 
interaction between age at diagnosis and size of tumor. Actual data was revealed that the 
analytical behavior of survival time as a function of age for Whites is linear in every 5 
years. Similarly, the analytical behavior of the survival time as a function of tumor size 
for Whites is linear in every 15mm. Thus, we performed parametric survival modeling, 
with collapsing age at diagnosis into ten groups and tumor size as three groups, to 
evaluate the survivorship for Whites under different treatment at each stage of prostate 
cancer. 
In stage I, White men have a better survival receiving radiation therapy, surgery, 
and combination of radiation and surgery than under watchful waiting. The 
corresponding estimated mean probability residual are 17.7%, 21.8%, and 20.7%, 
respectively. Moreover, the survivorship of White men undergoing surgery and 
combination of radiation and surgery are better than receiving radiation therapy. The 
corresponding estimated mean probabilities residual are 4.1% and 3.0%. However, the 
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survivorship of surgery and combination of radiation and surgery are approximately the 
same under 5% level of significance. 
In stage II, White men have a better survival receiving radiation therapy, surgery 
and combination of radiation surgery than under watchful waiting. The corresponding 
estimated mean probability residual are 15.7%, 21.2%, and 17.4%, respectively. 
Moreover, the survivorship of White men undergoing surgery and combination of 
radiation and surgery are better than receiving radiation therapy. The corresponding 
estimated mean probabilities residual are 5.5%, 1.8%, respectively. Also, the survivorship 
of surgery is better than combination of radiation and surgery with the estimated mean 
probability residual of 3.7%. 
In stage III, White men have a better survival receiving radiation therapy, surgery 
and combination of radiation surgery than under watchful waiting. The corresponding 
estimated mean probability residual are 15.9%, 22.2%, and 28.5%, respectively. 
Moreover, the survivorship of White men undergoing combination of radiation and 
surgery are better than receiving radiation therapy and undergoing surgery. The 
corresponding estimated mean probabilities residual are 12.5 %, 6.3%, respectively. Also, 
the survivorship of surgery is better than radiation therapy with the estimated mean 
probability residual of 6.2%. 
In stage IV, White men have a better survival receiving radiation therapy, surgery 
and combination of radiation surgery than under watchful waiting. The corresponding 
estimated mean probability residual are 18.2%, 21.0%, and 24.5%, respectively. 
Moreover, the survivorship of White men undergoing combination of radiation and 
surgery are better than receiving radiation therapy and undergoing surgery. The 
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corresponding estimated mean probabilities residual are 6.4%, 3.6%, respectively. Also, 
the survivorship of surgery is better than radiation therapy with the estimated mean 
probability residual of 2.8%. 
These findings will help physicians give an estimate of the survivorship for White 
men under different treatment at the four different stages of prostate cancer, and provide 
the most effective treatment for patients depending on their age, tumor size, and the stage 
of prostate cancer. 
4.7 Contributions 
In the present chapter are answered some important questions concerning prostate 
cancer. 
 Age at diagnosis, tumor size, and the interaction between age at diagnosis and 
tumor size are shown to be significantly contributed to the survival time for White 
men undergoing different treatment at some particular stages of prostate cancer.   
 We estimated the survival time using the parametric survival modeling and the 
best fitted probability distribution function that characterizes the behavior of the 
estimated survival times for White men is gamma distribution. 
 With the estimated survival time and their distribution, we have evaluated the 
estimated mean probability residual of Whites undergoing different treatments at 
a particular stage of prostate cancer. These findings will help physicians provide 
the most effective treatment and cost-effective strategies for white patients by 
knowing their age, tumor size, and the stage of prostate cancer. 
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CHAPTER 5 COMPARISON BETWEEN PARAMETRIC SURVIVAL ANALYSIS 
AND MODELING FOR WHITES WITH PROSTATE CANCER 
The objective of the present study is to compare the survivorship for white men 
under similar treatment at each stage of prostate cancer based on the results of parametric 
survival analysis in chapter 3 and parametric survival modeling in chapter 4. Due to the 
significant risk factors (age at diagnosis, tumor size, and interaction between age at 
diagnosis and tumor size), we would expect that the results of parametric survival 
modeling estimate better survivorship compared with the results of parametric survival 
analysis. To identify the average percentage differences in the two results, survival 
probability residuals will be calculated in this analysis. 
5.1 Survival Analysis VS. Survival Modeling for Whites in Stage I 
Case 0: No Treatment (Watchful Waiting) 
 In chapter 3, we have identified the appropriate probability distribution function 
that characterizes the behavior of the survival times for white men under watchful 
waiting in stage I is gamma distribution with the shape parameter,  ̂         and 
location parameter,   ̂        , while the best fitted probability function that 
characterizes the estimated survival time based on the survival regression model in 
chapter 4 is gamma distribution with the shape parameter,  ̂         and location 
parameter,  ̂        . Based on the distribution and their estimates, the corresponding 
E(x), median, and 95% confident limit are shown in Table 5.1. 
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Table 5.1 Descriptive Statistics of Parametric SA and SM for Whites under Watchful Waiting in Stage I 
  Expected Value E(x) Median 95% CI 
Survival Analysis (SA) 7.99 7.17 (1.76, 18.84) 
Survival Modeling (SM) 9.21 8.28 (2.07, 21.57) 
 
Table 5.1 showed that the survival modeling has better expected and median of the 
survival time compared with the results of survival analysis. More specifically, a 
graphical display of the survival function based on two methods for white men under 
watchful waiting is given by Figure 5.1. 
 
Figure 5.1 Survival Function for Whites under Watchful Waiting in Stage I: Results of SA vs. SM 
It appears that the survivorship of the results between the survival modeling and the 
survival analysis are approximately the same. We proceed to evaluate survival probability 
by discretizing the time points and results are shown in Table 5.2. 
In determining the average percentage differences for each year, we performed a 
comparison between two results at each time point is defined as survival probability 
residuals. 
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Table 5.2 Results of Survival Probability for SA and SM for Whites under Watchful Waiting in Stage I 
 Survival Probability 
Time in Year NT: SA NT: SM 
1 0.9948 0.9969 
2 0.9649 0.9773 
3 0.9041 0.9343 
4 0.8190 0.8699 
5 0.7198 0.7901 
6 0.6164 0.7019 
7 0.5164 0.6116 
8 0.4245 0.5239 
9 0.3433 0.4423 
10 0.2739 0.3685 
11 0.2158 0.3036 
12 0.1683 0.2476 
13 0.1300 0.2002 
14 0.0996 0.1605 
15 0.0757 0.1278 
16 0.0572 0.1011 
17 0.0429 0.0795 
18 0.0321 0.0622 
19 0.0238 0.0484 
20 0.0176 0.0375 
 
Let  ̂      represent the survival probability residual between the results of survival 
analysis and survival modeling for white men under watchful waiting in stage I. That is: 
  ̂      ̂        ̂                     
The estimated mean probability residual between the two results under watchful waiting 
in stage I is approximately 0.0573. A hypothesis test was performed to compare the 
significant differences between two similar treatment based on the results of survival 
analysis and survival modeling. The results were found significant difference under 
watchful waiting with a p-value of less than 0.0001. The nonparametric test also verified 
our decision and the results are consistent.  
111 
 
Case I: Radiation therapy 
 Based on the survival analysis, the best fitted probability distribution function that 
characterizes the behavior of the survival times for white men receiving radiation therapy 
in stage I is gamma distribution with the shape parameter,  ̂         and location 
parameter,   ̂       , while the results in the survival modeling is also gamma 
distribution with the shape parameter,  ̂         and location parameter,   ̂        . 
The corresponding E(x), median, and 95% confident limit are shown in Table 5.3. 
Table 5.3 Descriptive Statistics of Parametric SA and SM for Whites receiving Radiation Therapy in Stage I 
  Expected Value E(x) Median 95% CI 
Survival Analysis (SA) 9.27 8.65 (2.99, 19.04) 
Survival Modeling (SM) 13 12.23 (4.57, 25.75) 
 
The survival modeling has better expected value and median of the survival time 
compared with the results of survival analysis. More specifically, a graphical display of 
the survival function based on two methods for white men receiving radiation therapy is 
given by Figure 5.2. 
 
Figure 5.2 Survival Function for Whites receiving Radiation Therapy in Stage I: Results of SA vs. SM 
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Figure 5.2 revealed that the results of survival modeling have better survivorship than the 
results of survival analysis. We proceed to evaluate survival probability by discretizing 
the time points and results are shown in Table 5.4. 
Table 5.4 Results of Survival Probability for SA and SM for Whites receiving Radiation Therapy in Stage I 
 Survival Probability 
Time in Year Rad: SAS Rad: SMS 
1 0.9997 1.0000 
2 0.9948 0.9994 
3 0.9746 0.9959 
4 0.9308 0.9855 
5 0.8618 0.9643 
6 0.7725 0.9297 
7 0.6712 0.8813 
8 0.5665 0.8205 
9 0.4659 0.7501 
10 0.3742 0.6738 
11 0.2944 0.5952 
12 0.2273 0.5176 
13 0.1726 0.4435 
14 0.1292 0.3748 
15 0.0954 0.3128 
16 0.0695 0.2581 
17 0.0502 0.2106 
18 0.0358 0.1702 
19 0.0254 0.1362 
20 0.0178 0.1082 
 
In determining the average percentage differences for each year, we performed a 
comparison between two results at each time point. The estimated mean probability 
residual between the two results receiving radiation therapy in stage I is approximately 
0.1699. A hypothesis test was performed to compare the significant differences between 
two similar treatment based on the results of survival analysis and survival modeling. The 
results were found significant difference receiving radiation therapy with a p-value of less 
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than 0.0001. The nonparametric test also verified our decision and the results are 
consistent.  
Case II: Surgery 
Based on the survival analysis, the best fitted probability function that 
characterizes the behavior of the survival times for white men undergoing surgery in 
stage I is gamma distribution with the shape parameter,  ̂        and location 
parameter,   ̂        , while the results in the survival modeling is also gamma 
distribution with the shape parameter,  ̂         and location parameter,   ̂        . 
The corresponding E(x), median, and 95% confident limit are shown in Table 5.5. 
Table 5.5 Descriptive Statistics of Parametric SA and SM for Whites undergoing Surgery in Stage I 
  Expected Value E(x) Median 95% CI 
Survival Analysis (SA) 9.57 8.66 (2.25, 22.10) 
Survival Modeling (SM) 14.36 13.27 (4.18, 30.71) 
 
The survival modeling has better expected value and median of the survival time 
compared with the results of survival analysis. More specifically, a graphical display of 
the survival function based on two methods for white men undergoing surgery is given by 
Figure 5.3. 
Figure 5.3 revealed that the results of survival modeling have better survivorship 
than the results of survival analysis.  
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Figure 5.3 Survival Function for Whites undergoing Surgery in Stage I: Results of SA vs. SM 
We proceed to evaluate survival probability by discretizing the time points and results are 
shown in Table 5.6. 
Table 5.6 Results of Survival Probability for SA and SM for Whites undergoing Surgery in Stage I 
 Survival Probability 
Time in Year Surg: SA Surg: SM 
1 0.9978 0.9999 
2 0.9822 0.9983 
3 0.9455 0.9922 
4 0.8879 0.9785 
5 0.8140 0.9552 
6 0.7300 0.9217 
7 0.6419 0.8785 
8 0.5548 0.8270 
9 0.4723 0.7692 
10 0.3967 0.7073 
11 0.3293 0.6434 
12 0.2705 0.5793 
13 0.2201 0.5167 
14 0.1776 0.4569 
15 0.1423 0.4008 
16 0.1132 0.3489 
17 0.0895 0.3016 
18 0.0703 0.2591 
19 0.0550 0.2213 
20 0.0428 0.1879 
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In determining the average percentage differences for each year, we performed a 
comparison between two results at each time point. The estimated mean probability 
residual between the two results undergoing surgery in stage I is approximately 0.2005. A 
hypothesis test was performed to compare the significant differences between two similar 
treatment based on the results of survival analysis and survival modeling. The results 
were found significant difference undergoing surgery with a p-value of less than 0.0001. 
The nonparametric test also verified our decision and the results are consistent.  
Case III: Combination of Radiation and Surgery 
Based on the survival analysis, the best fitted probability function that 
characterizes the behavior of the survival times for white men receiving both radiation 
and surgery in stage I is gamma distribution with the shape parameter,  ̂         and 
location parameter,   ̂        , while the results in the survival modeling is also gamma 
distribution with the shape parameter,  ̂         and location parameter,   ̂        . 
The corresponding E(x), median, and 95% confident limit are shown in Table 5.7. 
Table 5.7 Descriptive Statistics of Parametric SA and SM for Whites receiving both Radiation and Surgery in Stage I 
  Expected Value E(x) Median 95% CI 
Survival Analysis (SA) 9.92 9.12 (2.75, 21.61) 
Survival Modeling (SM) 13.81 12.95 (4.66, 27.84) 
 
The survival modeling has better expected value and median of the survival time 
compared with the results of survival analysis. More specifically, a graphical display of 
the survival function based on two methods for white men receiving both radiation and 
surgery is given by Figure 5.4. 
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Figure 5.4 Survival Function for Whites receiving both Radiation and Surgery in Stage I: Results of SA vs. SM 
Figure 5.4 revealed that the results of survival modeling have better survivorship than the 
results of survival analysis. We proceed to evaluate survival probability by discretizing 
the time points and results are shown in Table 5.8. 
Table 5.8 Results of Survival Probability for SA and SM for Whites receiving both Radiation and Surgery in Stage I 
 Survival Probability 
Time in Year Comb: SA Comb: SM 
1 0.9993 1.0000 
2 0.9913 0.9993 
3 0.9669 0.9959 
4 0.9219 0.9864 
5 0.8572 0.9674 
6 0.7778 0.9370 
7 0.6897 0.8946 
8 0.5989 0.8412 
9 0.5104 0.7790 
10 0.4277 0.7107 
11 0.3531 0.6391 
12 0.2876 0.5669 
13 0.2315 0.4966 
14 0.1843 0.4299 
15 0.1453 0.3680 
16 0.1136 0.3119 
17 0.0881 0.2618 
18 0.0678 0.2179 
19 0.0518 0.1798 
20 0.0394 0.1473 
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In determining the average percentage differences for each year, we performed a 
comparison between two results at each time point. The estimated mean probability 
residual between the two results receiving both radiation and surgery in stage I is 
approximately 0.1714. A hypothesis test was performed to compare the significant 
differences between two similar treatment based on the results of survival analysis and 
survival modeling. The results were found significant difference receiving both radiation 
and surgery with a p-value of less than 0.0001. The nonparametric test also verified our 
decision and the results are consistent.  
5.2 Survival Analysis VS. Survival Modeling for Whites in Stage II 
Case 0: No Treatment (Watchful Waiting) 
 The appropriate probability distribution function that characterizes the behavior of 
the survival times for white men under watchful waiting in stage II based on survival 
analysis is gamma distribution with the shape parameter,  ̂         and location 
parameter,   ̂        , while the best fitted probability function that characterizes the 
estimated survival time based on the survival regression model is also gamma distribution 
with the shape parameter,  ̂         and location parameter,  ̂        . Based on the 
distribution and their estimates, the corresponding E(x), median, and 95% confident limit 
are shown in Table 5.9. 
Table 5.9 Descriptive Statistics of Parametric SA and SM for Whites under Watchful Waiting in Stage II 
  Expected Value E(x) Median 95% CI 
Survival Analysis (SA) 7.31 6.54 (1.56, 17.43) 
Survival Modeling (SM) 9.62 8.75 (2.39, 21.80) 
 
Table 5.9 showed that the survival modeling has better expected and median of the 
survival time compared with the results of survival analysis. More specifically, a 
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graphical display of the survival function based on two methods for white men under 
watchful waiting is given by Figure 5.5. 
 
Figure 5.5 Survival Function for Whites under Watchful Waiting in Stage II: Results of SA vs. SM 
It appears that the survivorship of the results between the survival modeling and the 
survival analysis are approximately the same. We proceed to evaluate survival probability 
by discretizing the time points and results are shown in Table 5.10. 
In determining the average percentage differences for each year, we performed a 
comparison between two results at each time point is defined as survival probability 
residuals. The estimated mean probability residual between the two results under 
watchful waiting in stage II is approximately 0.1104. A hypothesis test was performed to 
compare the significant differences between two similar treatment based on the results of 
survival analysis and survival modeling. The results were found significant difference 
under watchful waiting with a p-value of less than 0.0001. The nonparametric test also 
verified our decision and the results are consistent.  
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Table 5.10 Results of Survival Probability for SA and SM for Whites under Watchful Waiting in Stage II 
 Survival Probability 
Time in Year NT: SA NT: SM 
1 0.9924 0.9984 
2 0.9526 0.9852 
3 0.8774 0.9520 
4 0.7777 0.8973 
5 0.6671 0.8251 
6 0.5566 0.7414 
7 0.4539 0.6525 
8 0.3630 0.5636 
9 0.2856 0.4790 
10 0.2216 0.4012 
11 0.1698 0.3317 
12 0.1288 0.2712 
13 0.0968 0.2195 
14 0.0721 0.1760 
15 0.0534 0.1400 
16 0.0392 0.1105 
17 0.0287 0.0867 
18 0.0208 0.0676 
19 0.0151 0.0524 
20 0.0108 0.0404 
 
Case I: Radiation therapy 
 Based on the survival analysis, the appropriate probability distribution function 
that characterizes the behavior of the survival times for white men receiving radiation 
therapy in stage II is gamma distribution with the shape parameter,  ̂         and 
location parameter,   ̂        , while the results in the survival modeling is also gamma 
distribution with the shape parameter,  ̂         and location parameter,   ̂        . 
The corresponding E(x), median, and 95% confident limit are shown in Table 5.11. 
The survival modeling has better expected value and median of the survival time 
compared with the results of survival analysis. 
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Table 5.11 Descriptive Statistics of Parametric SA and SM for Whites receiving Radiation Therapy in Stage II 
  Expected Value E(x) Median 95% CI 
Survival Analysis (SA) 9.17 8.44 (2.55, 19.95) 
Survival Modeling (SM) 13.15 12.23 (4.09, 27.40) 
 
More specifically, a graphical display of the survival function based on two methods for 
white men receiving radiation therapy is given by Figure 5.6. 
 
Figure 5.6 Survival Function for Whites receiving Radiation Therapy in Stage II: Results of SA vs. SM 
Figure 5.6 revealed that the results of survival modeling have better survivorship than the 
results of survival analysis. We proceed to evaluate survival probability by discretizing 
the time points and results are shown in Table 5.12. 
In determining the average percentage differences for each year, we performed a 
comparison between two results at each time point. The estimated mean probability 
residual between the two results receiving radiation therapy in stage II is approximately 
0.1760. A hypothesis test was performed to compare the significant differences between 
two similar treatment based on the results of survival analysis and survival modeling. The 
results were found significant difference receiving radiation therapy with a p-value of less 
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than 0.0001. The nonparametric test also verified our decision and the results are 
consistent. 
Table 5.12 Results of Survival Probability for SA and SM for Whites receiving Radiation Therapy in Stage II 
 Survival Probability 
Time in Year Rad: SA Rad: SM 
1 0.9991 0.9999 
2 0.9889 0.9984 
3 0.9585 0.9921 
4 0.9037 0.9769 
5 0.8274 0.9501 
6 0.7365 0.9107 
7 0.6389 0.8595 
8 0.5414 0.7987 
9 0.4495 0.7310 
10 0.3665 0.6595 
11 0.2940 0.5870 
12 0.2325 0.5160 
13 0.1815 0.4483 
14 0.1401 0.3854 
15 0.1070 0.3281 
16 0.0810 0.2767 
17 0.0608 0.2315 
18 0.0453 0.1921 
19 0.0335 0.1583 
20 0.0246 0.1296 
 
Case II: Surgery 
Based on the survival analysis, the best fitted probability function that 
characterizes the behavior of the survival times for white men undergoing surgery in 
stage II is gamma distribution with the shape parameter,  ̂         and location 
parameter,   ̂        , while the results in the survival modeling is also gamma 
distribution with the shape parameter,  ̂         and location parameter,   ̂        . 
The corresponding E(x), median, and 95% confident limit are shown in Table 5.13. 
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Table 5.13 Descriptive Statistics of Parametric SA and SM for Whites undergoing Surgery in Stage II 
  Expected Value E(x) Median 95% CI 
Survival Analysis (SA) 10.44 9.71 (3.23, 21.80) 
Survival Modeling (SM) 14.42 13.56 (5.01, 28.71) 
 
The survival modeling has better expected value and median of the survival time 
compared with the results of survival analysis. More specifically, a graphical display of 
the survival function based on two methods for white men undergoing surgery is given by 
Figure 5.7. 
 
Figure 5.7 Survival Function for Whites undergoing Surgery in Stage II: Results of SA vs. SM 
Figure 5.7 revealed that the results of survival modeling have better survivorship than the 
results of survival analysis. We proceed to evaluate survival probability by discretizing 
the time points and results are shown in Table 5.14. 
In determining the average percentage differences for each year, we performed a 
comparison between two results at each time point. The estimated mean probability 
residual between the two results undergoing surgery in stage II is approximately 0.1699. 
A hypothesis test was performed to compare the significant differences between two 
similar treatment based on the results of survival analysis and survival modeling. The 
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results were found significant difference undergoing surgery with a p-value of less than 
0.0001. The nonparametric test also verified our decision and the results are consistent.  
Table 5.14 Results of Survival Probability for SA and SM for Whites undergoing Surgery in Stage II 
 Survival Probability 
Time in Year Surg: SA Surg: SM 
1 0.9998 1.0000 
2 0.9959 0.9996 
3 0.9809 0.9972 
4 0.9483 0.9901 
5 0.8959 0.9753 
6 0.8258 0.9502 
7 0.7430 0.9140 
8 0.6534 0.8669 
9 0.5626 0.8104 
10 0.4752 0.7467 
11 0.3944 0.6783 
12 0.3223 0.6080 
13 0.2596 0.5381 
14 0.2065 0.4706 
15 0.1624 0.4070 
16 0.1263 0.3483 
17 0.0973 0.2952 
18 0.0744 0.2480 
19 0.0563 0.2066 
20 0.0424 0.1707 
 
Case III: Combination of Radiation and Surgery 
Based on the survival analysis, the best fitted probability function that 
characterizes the behavior of the survival times for white men receiving both radiation 
and surgery in stage II is gamma distribution with the shape parameter,  ̂         and 
location parameter,   ̂        , while the results in the survival modeling is also gamma 
distribution with the shape parameter,  ̂         and location parameter,   ̂        . 
The corresponding E(x), median, and 95% confident limit are shown in Table 5.15. 
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Table 5.15 Descriptive Statistics of Parametric SA and SM for Whites receiving both Radiation and Surgery in Stage II 
  Expected Value E(x) Median 95% CI 
Survival Analysis (SA) 10.92 10.13 (3.32, 22.95) 
Survival Modeling (SM) 13.55 12.65 (4.39, 27.78) 
 
The survival modeling has better expected value and median of the survival time 
compared with the results of survival analysis. More specifically, a graphical display of 
the survival function based on two methods for white men receiving both radiation and 
surgery is given by Figure 5.8. 
 
Figure 5.8 Survival Function for Whites receiving both Radiation and Surgery in Stage II: Results of SA vs. SM 
Figure 5.8 revealed that the results of survival modeling have better survivorship than the 
results of survival analysis. We proceed to evaluate survival probability by discretizing 
the time points and results are shown in Table 5.16. 
In determining the average percentage differences for each year, we performed a 
comparison between two results at each time point. The estimated mean probability 
residual between the two results receiving both radiation and surgery in stage II is 
approximately 0.1119. A hypothesis test was performed to compare the significant 
differences between two similar treatment based on the results of survival analysis and 
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survival modeling. The results were found significant difference receiving both radiation 
and surgery with a p-value of less than 0.0001. The nonparametric test also verified our 
decision and the results are consistent.  
Table 5.16 Results of Survival Probability for SA and SM for Whites receiving both Radiation and Surgery in Stage II 
 Survival Probability 
Time in Year Comb: SA Comb: SM 
1 0.9998 1.0000 
2 0.9962 0.9990 
3 0.9825 0.9943 
4 0.9530 0.9823 
5 0.9056 0.9599 
6 0.8417 0.9255 
7 0.7653 0.8792 
8 0.6815 0.8226 
9 0.5953 0.7580 
10 0.5108 0.6884 
11 0.4313 0.6167 
12 0.3589 0.5453 
13 0.2948 0.4764 
14 0.2392 0.4116 
15 0.1920 0.3519 
16 0.1526 0.2980 
17 0.1202 0.2502 
18 0.0939 0.2083 
19 0.0728 0.1721 
20 0.0560 0.1412 
 
5.3 Survival Analysis VS. Survival Modeling for Whites in Stage III 
Case 0: No Treatment (Watchful Waiting) 
 The appropriate probability distribution function that characterizes the behavior of 
the survival times for white men under watchful waiting in stage III based on survival 
analysis is gamma distribution with the shape parameter,  ̂        and location 
parameter,   ̂        , while the best fitted probability function that characterizes the 
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estimated survival time based on the survival regression model is also gamma distribution 
with the shape parameter,  ̂         and location parameter,  ̂        . Based on the 
distribution and their estimates, the corresponding E(x), median, and 95% confident limit 
are shown in Table 5.17. 
Table 5.17 Descriptive Statistics of Parametric SA and SM for Whites under Watchful Waiting in Stage III 
  Expected Value E(x) Median 95% CI 
Survival Analysis (SA) 6.65 5.55 (0.76, 18.75) 
Survival Modeling (SM) 9.62 8.75 (2.39, 21.80) 
 
Table 5.17 showed that the survival modeling has better expected and median of the 
survival time compared with the results of survival analysis. More specifically, a 
graphical display of the survival function based on two methods for white men under 
watchful waiting is given by Figure 5.9. 
 
Figure 5.9 Survival Function for Whites under Watchful Waiting in Stage III: Results of SA vs. SM 
It appears that the survivorship of the results between the survival modeling and the 
survival analysis are approximately the same. We proceed to evaluate survival probability 
by discretizing the time points and results are shown in Table 5.18. 
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Table 5.18 Results of Survival Probability for SA and SM for Whites under Watchful Waiting in Stage III 
 Survival Probability 
Time in Year NT: SA NT: SM 
1 0.9599 0.9873 
2 0.8722 0.9458 
3 0.7657 0.8822 
4 0.6563 0.8049 
5 0.5527 0.7214 
6 0.4591 0.6371 
7 0.3773 0.5557 
8 0.3073 0.4798 
9 0.2485 0.4106 
10 0.1997 0.3488 
11 0.1596 0.2943 
12 0.1270 0.2469 
13 0.1007 0.2060 
14 0.0795 0.1712 
15 0.0626 0.1416 
16 0.0492 0.1168 
17 0.0385 0.0959 
18 0.0301 0.0786 
19 0.0235 0.0642 
20 0.0183 0.0523 
 
In determining the average percentage differences for each year, we performed a 
comparison between two results at each time point is defined as survival probability 
residuals. The estimated mean probability residual between the two results under 
watchful waiting in stage III is approximately 0.1077. A hypothesis test was performed to 
compare the significant differences between two similar treatment based on the results of 
survival analysis and survival modeling. The results were found significant difference 
under watchful waiting with a p-value of less than 0.0001. The nonparametric test also 
verified our decision and the results are consistent.  
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Case I: Radiation therapy 
 Based on the survival analysis, the appropriate probability distribution function 
that characterizes the behavior of the survival times for white men receiving radiation 
therapy in stage III is gamma distribution with the shape parameter,  ̂         and 
location parameter,   ̂        , while the results in the survival modeling is also gamma 
distribution with the shape parameter,  ̂         and location parameter,   ̂        . 
The corresponding E(x), median, and 95% confident limit are shown in Table 5.19. 
Table 5.19 Descriptive Statistics of Parametric SA and SM for Whites receiving Radiation Therapy in Stage III 
  Expected Value E(x) Median 95% CI 
Survival Analysis (SA) 8.83 7.94 (1.99, 20.67) 
Survival Modeling (SM) 12.49 11.38 (3.17, 28.10) 
 
The survival modeling has better expected value and median of the survival time 
compared with the results of survival analysis. More specifically, a graphical display of 
the survival function based on two methods for white men receiving radiation therapy is 
given by Figure 5.10. 
 
Figure 5.10 Survival Function for Whites receiving Radiation Therapy in Stage III: Results of SA vs. SM 
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Figure 5.10 revealed that the results of survival modeling have better survivorship than 
the results of survival analysis. We proceed to evaluate survival probability by 
discretizing the time points and results are shown in Table 5.20. 
Table 5.20 Results of Survival Probability for SA and SM for Whites receiving Radiation Therapy in Stage III 
 Survival Probability 
Time in Year Rad: SA Rad: SM 
1 0.9965 0.9994 
2 0.9745 0.9940 
3 0.9271 0.9787 
4 0.8570 0.9508 
5 0.7716 0.9101 
6 0.6785 0.8581 
7 0.5847 0.7975 
8 0.4950 0.7312 
9 0.4126 0.6621 
10 0.3394 0.5927 
11 0.2760 0.5251 
12 0.2220 0.4608 
13 0.1770 0.4009 
14 0.1400 0.3461 
15 0.1099 0.2966 
16 0.0857 0.2525 
17 0.0665 0.2137 
18 0.0512 0.1799 
19 0.0393 0.1506 
20 0.0300 0.1255 
 
In determining the average percentage differences for each year, we performed a 
comparison between two results at each time point. The estimated mean probability 
residual between the two results receiving radiation therapy in stage III is approximately 
0.1596. A hypothesis test was performed to compare the significant differences between 
two similar treatment based on the results of survival analysis and survival modeling. The 
results were found significant difference receiving radiation therapy with a p-value of less 
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than 0.0001. The nonparametric test also verified our decision and the results are 
consistent.  
Case II: Surgery 
Based on the survival analysis, the best fitted probability function that 
characterizes the behavior of the survival times for white men undergoing surgery in 
stage III is gamma distribution with the shape parameter,  ̂        and location 
parameter,   ̂       , while the results in the survival modeling is also gamma 
distribution with the shape parameter,  ̂         and location parameter,   ̂        . 
The corresponding E(x), median, and 95% confident limit are shown in Table 5.21. 
Table 5.21 Descriptive Statistics of Parametric SA and SM for Whites undergoing Surgery in Stage III 
  Expected Value E(x) Median 95% CI 
Survival Analysis (SA) 11.39 10.81 (4.38, 21.70) 
Survival Modeling (SM) 13.53 12.86 (5.31, 25.52) 
 
The survival modeling has better expected value and median of the survival time 
compared with the results of survival analysis. More specifically, a graphical display of 
the survival function based on two methods for white men undergoing surgery is given by 
Figure 5.11. 
 
Figure 5.11 Survival Function for Whites undergoing Surgery in Stage III: Results of SA vs. SM 
20151050
1.0
0.8
0.6
0.4
0.2
0.0
Time in Year
S
u
rv
iv
a
l 
P
ro
b
a
b
ili
ty
Surg: SA
Surg: SM
Variable
Survival Function for Whites undergoing Surgery in Stage III: SA vs. SM
131 
 
Figure 5.11 revealed that the results of survival modeling have better survivorship than 
the results of survival analysis. We proceed to evaluate survival probability by 
discretizing the time points and results are shown in Table 5.22. 
Table 5.22 Results of Survival Probability for SA and SM for Whites undergoing Surgery in Stage III 
 Survival Probability 
Time in Year Surg: SA Surg: SM 
1 1.0000 1.0000 
2 0.9995 0.9999 
3 0.9959 0.9986 
4 0.9834 0.9936 
5 0.9560 0.9810 
6 0.9095 0.9572 
7 0.8440 0.9197 
8 0.7628 0.8680 
9 0.6714 0.8038 
10 0.5763 0.7300 
11 0.4829 0.6504 
12 0.3959 0.5689 
13 0.3180 0.4890 
14 0.2507 0.4135 
15 0.1943 0.3443 
16 0.1483 0.2826 
17 0.1116 0.2289 
18 0.0828 0.1831 
19 0.0608 0.1449 
20 0.0441 0.1134 
 
In determining the average percentage differences for each year, we performed a 
comparison between two results at each time point. The estimated mean probability 
residual between the two results undergoing surgery in stage III is approximately 0.0941. 
A hypothesis test was performed to compare the significant differences between two 
similar treatment based on the results of survival analysis and survival modeling. The 
results were found significant difference undergoing surgery with a p-value of less than 
0.0001. The nonparametric test also verified our decision and the results are consistent.  
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Case III: Combination of Radiation and Surgery 
Based on the survival analysis, the best fitted probability function that 
characterizes the behavior of the survival times for white men receiving both radiation 
and surgery in stage III is gamma distribution with the shape parameter,  ̂         and 
location parameter,   ̂        , while the results in the survival modeling is also gamma 
distribution with the shape parameter,  ̂         and location parameter,   ̂        . 
The corresponding E(x), median, and 95% confident limit are shown in Table 5.23. 
Table 5.23 Descriptive Statistics of Parametric SA and SM for Whites receiving both Radiation and Surgery in Stage 
III 
  Expected Value E(x) Median 95% CI 
Survival Analysis (SA) 11.08 10.42 (3.86, 22.05) 
Survival Modeling (SM) 15.30 14.46 (5.63, 29.74) 
 
The survival modeling has better expected value and median of the survival time 
compared with the results of survival analysis. More specifically, a graphical display of 
the survival function based on two methods for white men receiving both radiation and 
surgery is given by Figure 5.12. 
 
Figure 5.12 Survival Function for Whites receiving both Radiation and Surgery in Stage III: Results of SA vs. SM 
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Figure 5.12 revealed that the results of survival modeling have better survivorship than 
the results of survival analysis. We proceed to evaluate survival probability by 
discretizing the time points and results are shown in Table 5.24. 
Table 5.24 Results of Survival Probability for SA and SM for Whites receiving both Radiation and Surgery in Stage III 
 Survival Probability 
Time in Year Comb: SA Comb: SM 
1 1.0000 1.0000 
2 0.9986 0.9998 
3 0.9912 0.9987 
4 0.9713 0.9946 
5 0.9337 0.9849 
6 0.8773 0.9673 
7 0.8044 0.9399 
8 0.7197 0.9020 
9 0.6289 0.8542 
10 0.5377 0.7978 
11 0.4505 0.7349 
12 0.3705 0.6679 
13 0.2996 0.5992 
14 0.2385 0.5310 
15 0.1873 0.4650 
16 0.1452 0.4029 
17 0.1112 0.3454 
18 0.0843 0.2933 
19 0.0632 0.2468 
20 0.0470 0.2060 
 
In determining the average percentage differences for each year, we performed a 
comparison between two results at each time point. The estimated mean probability 
residual between the two results receiving both radiation and surgery in stage III is 
approximately 0.1736. A hypothesis test was performed to compare the significant 
differences between two similar treatment based on the results of survival analysis and 
survival modeling. The results were found significant difference receiving both radiation 
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and surgery with a p-value of less than 0.0001. The nonparametric test also verified our 
decision and the results are consistent. 
5.4 Survival Analysis VS. Survival Modeling for Whites in Stage IV 
Case 0: No Treatment (Watchful Waiting) 
 The appropriate probability distribution function that characterizes the behavior of 
the survival times for white men under watchful waiting in stage IV based on survival 
analysis is gamma distribution with the shape parameter,  ̂         and location 
parameter,   ̂        , while the best fitted probability function that characterizes the 
estimated survival time based on the survival regression model is also gamma distribution 
with the shape parameter,  ̂         and location parameter,  ̂        . Based on the 
distribution and their estimates, the corresponding E(x), median, and 95% confident limit 
are shown in Table 5.25. 
Table 5.25 Descriptive Statistics of Parametric SA and SM for Whites under Watchful Waiting in Stage IV 
  Expected Value E(x) Median 95% CI 
Survival Analysis (SA) 4.57 3.43 (0.22, 15.28) 
Survival Modeling (SM) 6.30 5.05 (0.52, 19.10) 
 
Table 5.25 showed that the survival modeling has better expected and median of the 
survival time compared with the results of survival analysis. More specifically, a 
graphical display of the survival function based on two methods for white men under 
watchful waiting is given by Figure 5.13. 
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Figure 5.13 Survival Function for Whites under Watchful Waiting in Stage IV: Results of SA vs. SM 
It appears that the survivorship of the results between the survival modeling and the 
survival analysis are approximately the same. We proceed to evaluate survival probability 
by discretizing the time points and results are shown in Table 5.26. 
Table 5.26 Results of Survival Probability for SA and SM for Whites under Watchful Waiting in Stage IV 
 Survival Probability 
Time in Year NT: SA NT: SM 
1 0.8512 0.9338 
2 0.6916 0.8265 
3 0.5526 0.7122 
4 0.4374 0.6034 
5 0.3440 0.5051 
6 0.2693 0.4189 
7 0.2100 0.3450 
8 0.1634 0.2825 
9 0.1268 0.2302 
10 0.0982 0.1868 
11 0.0760 0.1512 
12 0.0587 0.1219 
13 0.0453 0.0981 
14 0.0349 0.0788 
15 0.0269 0.0631 
16 0.0207 0.0505 
17 0.0159 0.0403 
18 0.0122 0.0321 
19 0.0094 0.0256 
20 0.0072 0.0203 
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In determining the average percentage differences for each year, we performed a 
comparison between two results at each time point is defined as survival probability 
residuals. The estimated mean probability residual between the two results under 
watchful waiting in stage IV is approximately 0.0837. A hypothesis test was performed to 
compare the significant differences between two similar treatment based on the results of 
survival analysis and survival modeling. The results were found significant difference 
under watchful waiting with a p-value of less than 0.0001. The nonparametric test also 
verified our decision and the results are consistent. 
Case I: Radiation therapy 
 Based on the survival analysis, the appropriate probability distribution function 
that characterizes the behavior of the survival times for white men receiving radiation 
therapy in stage IV is gamma distribution with the shape parameter,  ̂         and 
location parameter,   ̂        , while the results in the survival modeling is also gamma 
distribution with the shape parameter,  ̂         and location parameter,   ̂        . 
The corresponding E(x), median, and 95% confident limit are shown in Table 5.27. 
Table 5.27 Descriptive Statistics of Parametric SA and SM for Whites receiving Radiation Therapy in Stage IV 
  Expected Value E(x) Median 95% CI 
Survival Analysis (SA) 6.75 5.61 (0.75, 19.21) 
Survival Modeling (SM) 10.22 8.95 (1.80, 25.80) 
 
The survival modeling has better expected value and median of the survival time 
compared with the results of survival analysis. More specifically, a graphical display of 
the survival function based on two methods for white men receiving radiation therapy is 
given by Figure 5.14. 
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Figure 5.14 Survival Function for Whites receiving Radiation Therapy in Stage IV: Results of SA vs. SM 
Figure 5.14 revealed that the results of survival modeling have better survivorship than 
the results of survival analysis. We proceed to evaluate survival probability by 
discretizing the time points and results are shown in Table 5.28. 
Table 5.28 Results of Survival Probability for SA and SM for Whites receiving Radiation Therapy in Stage IV 
 
Survival Probability 
Time in Year Rad: SA Rad: SM 
1 0.9585 0.9938 
2 0.8710 0.9681 
3 0.7660 0.9229 
4 0.6586 0.8626 
5 0.5570 0.7925 
6 0.4650 0.7174 
7 0.3843 0.6412 
8 0.3150 0.5669 
9 0.2565 0.4964 
10 0.2076 0.4310 
11 0.1672 0.3716 
12 0.1341 0.3183 
13 0.1071 0.2710 
14 0.0853 0.2296 
15 0.0677 0.1936 
16 0.0536 0.1626 
17 0.0424 0.1360 
18 0.0334 0.1134 
19 0.0263 0.0942 
20 0.0207 0.0780 
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In determining the average percentage differences for each year, we performed a 
comparison between two results at each time point. The estimated mean probability 
residual between the two results receiving radiation therapy in stage IV is approximately 
0.1592. A hypothesis test was performed to compare the significant differences between 
two similar treatment based on the results of survival analysis and survival modeling. The 
results were found significant difference receiving radiation therapy with a p-value of less 
than 0.0001. The nonparametric test also verified our decision and the results are 
consistent. 
Case II: Surgery 
Based on the survival analysis, the best fitted probability function that 
characterizes the behavior of the survival times for white men undergoing surgery in 
stage IV is gamma distribution with the shape parameter,  ̂         and location 
parameter,   ̂        , while the results in the survival modeling is also gamma 
distribution with the shape parameter,  ̂         and location parameter,   ̂        . 
The corresponding E(x), median, and 95% confident limit are shown in Table 5.29. 
Table 5.29 Descriptive Statistics of Parametric SA and SM for Whites undergoing Surgery in Stage IV 
  Expected Value E(x) Median 95% CI 
Survival Analysis (SA) 8.12 7.30 (1.83, 18.96) 
Survival Modeling (SM) 10.64 9.72 (2.76, 23.74) 
 
The survival modeling has better expected value and median of the survival time 
compared with the results of survival analysis. More specifically, a graphical display of 
the survival function based on two methods for white men undergoing surgery is given by 
Figure 5.15. 
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Figure 5.15 Survival Function for Whites undergoing Surgery in Stage IV: Results of SA vs. SM 
Figure 5.15 revealed that the results of survival modeling have better survivorship than 
the results of survival analysis. We proceed to evaluate survival probability by 
discretizing the time points and results are shown in Table 5.30. 
In determining the average percentage differences for each year, we performed a 
comparison between two results at each time point. The estimated mean probability 
residual between the two results undergoing surgery in stage IV is approximately 0.1184. 
A hypothesis test was performed to compare the significant differences between two 
similar treatment based on the results of survival analysis and survival modeling. The 
results were found significant difference undergoing surgery with a p-value of less than 
0.0001. The nonparametric test also verified our decision and the results are consistent. 
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Table 5.30 Results of Survival Probability for SA and SM for Whites undergoing Surgery in Stage IV 
 
Survival Probability 
Time in Year Surg: SA Surg: SM 
1 0.9956 0.9991 
2 0.9683 0.9909 
3 0.9110 0.9680 
4 0.8288 0.9272 
5 0.7315 0.8697 
6 0.6288 0.7992 
7 0.5285 0.7205 
8 0.4357 0.6384 
9 0.3533 0.5568 
10 0.2823 0.4788 
11 0.2229 0.4065 
12 0.1740 0.3413 
13 0.1345 0.2836 
14 0.1031 0.2335 
15 0.0784 0.1907 
16 0.0593 0.1545 
17 0.0445 0.1244 
18 0.0332 0.0994 
19 0.0247 0.0791 
20 0.0182 0.0625 
 
Case III: Combination of Radiation and Surgery 
Based on the survival analysis, the best fitted probability function that 
characterizes the behavior of the survival times for white men receiving both radiation 
and surgery in stage IV is gamma distribution with the shape parameter,  ̂         and 
location parameter,   ̂       , while the results in the survival modeling is also gamma 
distribution with the shape parameter,  ̂         and location parameter,   ̂        . 
The corresponding E(x), median, and 95% confident limit are shown in Table 5.31. 
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Table 5.31 Descriptive Statistics of Parametric SA and SM for Whites receiving both Radiation and Surgery in Stage 
IV 
  Expected Value E(x) Median 95% CI 
Survival Analysis (SA) 8.70 7.77 (1.83, 20.82) 
Survival Modeling (SM) 11.51 10.47 (2.86, 26.07) 
 
The survival modeling has better expected value and median of the survival time 
compared with the results of survival analysis. More specifically, a graphical display of 
the survival function based on two methods for white men receiving both radiation and 
surgery is given by Figure 5.16. 
 
Figure 5.16 Survival Function for Whites receiving both Radiation and Surgery in Stage IV: Results of SA vs. SM 
Figure 5.16 revealed that the results of survival modeling have better survivorship than 
the results of survival analysis. We proceed to evaluate survival probability by 
discretizing the time points and results are shown in Table 5.32. 
In determining the average percentage differences for each year, we performed a 
comparison between two results at each time point. The estimated mean probability 
residual between the two results receiving both radiation and surgery in stage IV is 
approximately 0.1268. A hypothesis test was performed to compare the significant 
differences between two similar treatment based on the results of survival analysis and 
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survival modeling. The results were found significant difference receiving both radiation 
and surgery with a p-value of less than 0.0001. The nonparametric test also verified our 
decision and the results are consistent. 
Table 5.32 Results of Survival Probability for SA and SM for Whites receiving both Radiation and Surgery in Stage IV 
 
Survival Probability 
Time in Year Comb: SA Comb: SM 
1 0.9951 0.9991 
2 0.9685 0.9916 
3 0.9156 0.9713 
4 0.8414 0.9359 
5 0.7537 0.8861 
6 0.6605 0.8246 
7 0.5679 0.7551 
8 0.4804 0.6812 
9 0.4007 0.6064 
10 0.3302 0.5332 
11 0.2692 0.4637 
12 0.2174 0.3994 
13 0.1741 0.3408 
14 0.1384 0.2885 
15 0.1094 0.2425 
16 0.0859 0.2024 
17 0.0670 0.1679 
18 0.0521 0.1385 
19 0.0403 0.1137 
20 0.0311 0.0929 
 
5.5 Conclusion 
In this study, we performed to compare the results of parametric survival analysis 
in chapter 3 and parametric survival modeling in chapter 4 to evaluate the survivorship 
for white men under similar treatment at four stages of prostate cancer. We found that 
white men always had better survivorship in the results of survival modeling across 
different treatments and the stage of prostate cancer. These might be due to the fact that 
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age at diagnosis, tumor size, and the interaction between age at diagnosis and tumor size 
play an important role in determining the prostate cancer patients’ survival times.   
Based on the results of survival model in stage I, White men have a better 
survivorship under watchful waiting, receiving radiation therapy, surgery, and 
combination of radiation and surgery based on the results of survival model. The 
corresponding estimated mean probability residual are 5.7%, 17.0%, 20.1%, and 17.1%, 
respectively. These findings indicated that age at diagnosis, tumor size, and the 
interaction between age at diagnosis and tumor size are the strong predictors of survival 
time for white men undergoing surgery. 
Based on the results of survival model in stage II, White men have a better 
survivorship under watchful waiting, receiving radiation therapy, surgery and 
combination of radiation surgery. The corresponding estimated mean probability residual 
are 11.0%, 17.6%, 17.0%, and 11.2%, respectively. These findings indicated that age at 
diagnosis, tumor size, and the interaction between age at diagnosis and tumor size are the 
strong predictors of survival time for white men receiving radiation therapy. 
Based on the results of survival model in stage III, White men have a better 
survivorship under watchful waiting, receiving radiation therapy, surgery, and 
combination of radiation and surgery based on the results of survival model. The 
corresponding estimated mean probability residual are 10.8%, 16.0%, 9.4%, and 17.4%, 
respectively. These findings indicated that age at diagnosis, tumor size, and the 
interaction between age at diagnosis and tumor size are the strong predictors of survival 
time for white men receiving both radiation therapy and surgery.  
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Based on the results of survival model in stage IV, White men have a better 
survivorship under watchful waiting, receiving radiation therapy, surgery and 
combination of radiation surgery. The corresponding estimated mean probability residual 
are 8.4%, 15.9%, 11.8%, and 12.7%, respectively. These findings indicated that age at 
diagnosis, tumor size, and the interaction between age at diagnosis and tumor size are the 
strong predictors of survival time for white men receiving radiation therapy. 
The above findings will help physicians identify the necessary of knowing white 
patient’s age, tumor size depending on the different treatment at the four different stages 
of prostate cancer, and provide the most cost-effective treatment for the patients.   
5.6 Contributions 
The present chapter are answered some important questions concerning prostate 
cancer. 
 Age at diagnosis, tumor size, and the interaction between age at diagnosis and 
tumor size are the keys to determine the survivorship for White men undergoing 
different treatment at some particular stages of prostate cancer.   
 We evaluated the average percentage differences in survivorship for white men 
undergoing similar treatment at each stage of prostate cancer based on the results 
of survival analysis and survival modeling. These findings will help physicians 
decide the necessary of identifying white patient’s age, tumor size depending on 
the different treatment at each stage of prostate cancer, and provide the most cost-
effective treatment for the patients. 
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CHAPTER 6 FUTURE RESEARCH 
To improve the accelerated failure models, we could increase the number of 
attributed variables that are significant predictors of survival time. Other database such as 
SEER could provide relevant risk factors of prostate cancer such as family history, 
smoking status, and drinking habits. These would help to understand the characteristics of 
health behaviors associated with survivorship for prostate cancer patients. Moreover, 
Bayesian approach might increase the strength of the model. Suppose we have enough 
estimates to justify the prior probability distribution of the parameter(s), which behave as 
a random variable, we could be able to estimate the survival time under the choice of a 
loss function such as squared-error loss function, which is one of the most widely used 
loss function. In fact, prior research showed that Bayesian approach produces a better 
estimate for the parameter compared with maximum likelihood estimation (MLE) 
approach (Molinares, 2011).
The other future work could include Markov analysis to examine the progression 
of prostate cancer patients who took different treatments at the four different stages. We 
could calculate the transition matrix that shows the probability of patients who receiving 
a particular treatment from one stage to different stage. These will help to evaluate the 
effectiveness of prostate cancer treatments.  
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